Radioactive embolizing compositions

专利摘要:
Disclosed are novel radioactive compositions which are particularly suited for treating solid mass tumors via catheter delivery.
公开号:US20010009656A1
申请号:US09/785,274
申请日:2001-02-20
公开日:2001-07-26
发明作者:Richard Greff；George Wallace
申请人:Greff Richard J.；George Wallace；
IPC主号:A61K51-06

专利说明:
[0001] 1. Field of the Invention [0001]
[0002] This invention is directed to novel compositions for delivery in vivo and preferably to vascular sites. Such compositions are particularly suited for treating solid mass tumors via catheter delivery of the composition to a vascular site leading to or in the solid mass tumor and subsequent embolization of this vascular site. [0002]
[0003] In particular, the compositions of this invention comprise a biocompatible polymer, a biocompatible solvent and a radioactive agent which provides therapeutic doses of radiation. [0003] REFERENCES
[0004] The following publications are cited in this application as superscript numbers: [0004]
[0005] [0005] ¹ Mandai, et al., “Direct Thrombosis of Aneurysms with Cellulose Acetate Polymer”, J. Neurosurg., 77:497-500 (1992)
[0006] [0006] ² Kinugas, et al., “Direct Thrombois of Aneurysms with Cellulose Acetate Polymer”, J. Neurosurg., 77:501-507 (1992)
[0007] [0007] ³ Casarett and Doull's Toxicology, Amdur, et al., Editors, Pergamon Press, New York, pp. 661-664 (1975)
[0008] [0008] ⁴ Greff, et al., U.S. Pat. No. 5,667,767, for “Novel Compositions for Use in Embolizing Blood Vessels”, issued Sep. 16, 1997
[0009] [0009] ⁵ Greff, et al., U.S. Pat. No. 5,580,568 for “Cellulose Diacetate Compositions for Use in Embolizing Blood Vessels”, issued Dec. 3, 1996
[0010] [0010] ⁶ Kinugasa, et al., “Early Treatment of Subarachnoid Hemorrhage After Preventing Rerupture of an Aneurysm”, J. Neurosurg., 83:34- 41 (1995)
[0011] [0011] ⁷ Kinugasa, et al., “Prophylactic Thrombosis to Prevent New Bleeding and to Delay Aneurysm Surgery”, Neurosurg., 36:661 (1995)
[0012] [0012] ⁸ Taki, et al., “Selection and Combination of Various Endovascular Techniques in the Treatment of Giant Aneurysms”, J. Neurosurg., 77:37-24 (1992)
[0013] [0013] ⁹ Evans, et al., U.S. patent application Ser. No. 08/802,252 for “Novel Compositions for Use in Embolizing Blood Vessels”, filed Feb. 19, 1997
[0014] [0014] ¹⁰ Castaneda-Zuniga, et al., Interventional Radiology, in Vascular Embolotherapy, Part 1, 1:9-32, Williams & Wilkins, Publishers (1992)
[0015] [0015] ¹¹ Rabinowitz, et al., U.S. Pat. No. 3,527,224 for “Method of Surgically Bonding Tissue Together”, issued Sep. 8, 1970
[0016] [0016] ¹² Hawkins, et al., U.S. Pat. No. 3,591,676 for “Surgical Adhesive Compositions”, issued Jul. 6, 1971
[0017] [0017] ¹³ Encyclopedia of Medical Devices and Instrumentation, J. G. Webster, Editor (1988) 4:2456
[0018] [0018] ¹⁴ Tanabe, U.S. Pat. No. 5,443,454 for “Catheter for Embolectomy”, issued Aug. 22, 1995
[0019] [0019] ¹⁵ Sitton, “Early and Late Radiation-Induced Skin Alterations Part I:Mechanisms of Skin Changes”, Oncology Nursing Forun, 19(5): 801-807 (1992)
[0020] [0020] ¹⁶ Dunn, et al., U.S. Pat. No. 4,938,763 for “Biodegradable In-Situ Forming Implants and Methods of Producing Same”, issued Jul. 3, 1990
[0021] [0021] ¹⁷ Hellman, “CANCER, Principles & Practice of Oncology”, 4th Ed., Volume 1, Chapter 15, “Principles of Radiation Therapy”, pp. 248-250 (1993)
[0022] [0022] ¹⁸ “CANCER, Principles & Practice of Oncology”, 4th Ed., Volume 1, “Cancer Treatment”, pp. 545-548 (1993)
[0023] All of the above publications are herein incorporated by reference in their entirety to the same extent as if each individual reference was specifically and individually indicated to be incorporated herein by reference in its entirety. [0023]
[0024] 2. State of the Art [0024]
[0025] Current therapeutic regimens for treating solid mass tumors in mammals include radiation therapy, vascular embolization, chemotherapy with cytotoxic agents, open surgery, and the like as well as combinations of two or more of the above. [0025]
[0026] Radiation therapy includes both the external and internal exposure of the tumor to ionizing radiation to induce tumor necrosis. In a first instance, application of external sources of radiation, known as teletherapy, has been used to treat solid mass tumors. Such external radiation sources include X-rays from a linear accelerator, gamma-rays generated from isotopes such as cobalt-60 (administered with a telecobalt apparatus) and electron beams generated from specialized radiotherapy machines or high energy linear accelerators. The use of external sources of radiation requires careful preplanning so that the patient is placed in the exact position necessary to treat the solid mass tumor. The precise positioning of the patient and application of radiation is important so as to minimize irradiation and tissue damage to unintended areas of the body. Nevertheless, external irradiation of the tumor induces skin damage to the exposed skin[0026] ¹⁵ and is not amenable to deep tumors because the external radiation gives unwanted tissue absorption around the tumor area.
[0027] Another technique, brachytherapy, is internal radiotherapy on solid mass tumors in a mammal by the in vivo placement of radioactive sources close to or in the tumor where destruction of non-cancerous tissue is limited.[0027] ¹⁷ Specifically, the dose distribution of the radiation is determined by the inverse square law and, accordingly, radiation effects on tissues at any distance from the radioactive source is limited. Examples of brachytherapy are interstitial or intracavitary radiation used in the treatment of many urologic, lung, gynecological and oral tumors. In one example of this technique, a removable applicator is used to direct radiation to desired areas while limiting exposure to other tissues. Nevertheless, brachytherapy is not amenable to tumors inaccessible by conventional surgical techniques.
[0028] Still another technique for the treatment of solid mass tumors is vascular embolization of blood vessels feeding the tumor to induce necrosis of the tumor tissue by obstructing its arterial supply. One preferred example of this technique is direct embolization of blood vessels by, e.g., catheter techniques which permit the selective placement of the catheter at the vascular site to be embolized which can be as small as 1 mm in diameter. [0028]
[0029] Preferred embolic compositions for catheter delivery to the vascular site include a biocompatible solvent, a biocompatible polymer and a contrast agent.[0029] ^{1-8, 14} The biocompatible solvent is miscible or soluble in blood or other body fluid and also solubilizes the biocompatible polymer during delivery. The biocompatible polymer is selected to be soluble in the biocompatible solvent but insoluble in blood or other body fluid. The contrast agent is selected to permit the physician to fluoroscopically visualize delivery of this composition. Upon contact with the blood or other body fluids, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates in the presence of the water insoluble contrast agent and embolizes the blood vessel.
[0030] The use of vascular embolization, by itself, in the treatment of solid mass tumors is complicated by the fact that, upon embolization of the blood vessel feeding the tumor, alternative vascular routes can be generated by the tumor which continue to feed the tumor. [0030]
[0031] Another example of embolization techniques in the treatment of solid mass tumors is termed “chemoembolization” which combines the use of intra-arterial high-dose chemotherapy with obstruction of the tumor vascular bed to provide a two-prong attack on the tumor.[0031] ¹⁷ The chemotherapeutic agent leaches from the deposited embolic agent to provide prolonged exposure time of the tumor to the chemotherapeutic agent and the embolic agent adds an ischemic component to enhance tumor necrosis. One example of this technique includes the placement of particulate carriers with chemotherapeutic agents bound to microspheres or contained in microcapsules (e.g., liposomes) at the vascular site.
[0032] However, the chemotherapeutic agent is susceptible to migration and systemic delivery in vivo with potential side effects in the patient. [0032]
[0033] In view of the above, there exists a continuing need to improve the treatment regimens for therapeutically treating solid mass tumors and, in particular, in vivo treatment of such tumors. [0033] SUMMARY OF THE INVENTION
[0034] This invention is directed to novel embolic compositions comprising a radioactive agent which are delivered e.g., to the vascular site, as a fluid and which solidify in vivo to form a solid, coherent mass. In a preferred embodiment, these compositions are employed in novel methods to embolize blood vessels supplying blood to a solid mass tumor as well as to provide therapeutic levels of radiation to the blood vessel and/or surrounding tissue. These novel methods allow for treatment of otherwise inoperable tumors by the catheter delivery of such embolic compositions to vascular sites. [0034]
[0035] Accordingly, in one of its composition aspects, this invention is directed to a composition comprising: [0035]
[0036] (a) a biocompatible polymer; [0036]
[0037] (b) a biocompatible solvent; and [0037]
[0038] (c) from about 0.1 to about 25 weight percent of a water insoluble radioisotope having a radioactive content of from about 0.5 microcurie to about 100 millicuries. [0038]
[0039] In a preferred embodiment, the amount and radioactive content of the radioisotope is sufficient to provide for a cumulative ionizing radiation dosage at the site of implantation in a mammalian subject of from about 200 to about 10,000 rads [2-100 Gray (Gy)]. [0039]
[0040] In a more preferred embodiment, these compositions are employed to effect necrosis of at least a portion of a solid mass tumor in the mammal. Accordingly, these compositions are delivered, for example, directly to the solid mass tumor or to a vascular site selected to be in or near the solid mass tumor and the amount and radioactive content of the radioisotope employed in the composition is sufficient to effect such necrosis. [0040]
[0041] Accordingly, in one of its method aspects, this invention is directed to a method for embolizing a blood vessel leading to or in a solid mass tumor in a mammal and causing necrosis to a portion of said solid mass tumor which method comprises: [0041]
[0042] (a) identifying a blood vessel in said mammal which leads to or is in the solid mass tumor; [0042]
[0043] (b) injecting a sufficient amount of an embolic composition comprising a biocompatible polymer, a biocompatible solvent and a water insoluble radioisotope into said blood vessel under conditions wherein a precipitate is formed which embolizes the blood vessel and further wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of said tumor. [0043]
[0044] In another of its method aspects, this invention is directed to a method for causing necrosis to a portion of a solid mass tumor which method comprises: [0044]
[0045] (a) identifying a solid mass tumor in a mammal; [0045]
[0046] (b) injecting a sufficient amount of an embolic composition comprising a biocompatible polymer, a biocompatible solvent and a water insoluble radioisotope into said tumor under conditions wherein a precipitate is formed wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of said tumor. [0046]
[0047] The biocompatible polymer employed in these compositions and methods can be either a biodegradable polymer or a non-biodegradable polymer but is, preferably, a non-biodegradable polymer. [0047]
[0048] In one embodiment, the radioisotope acts as a contrast agent to permit visualization of the composition during catheter delivery. Alternatively, a non-radioactive contrast agent is employed in combination with the radioisotope in order to ensure visualization. [0048]
[0049] In another embodiment, the biocompatible polymer can be replaced with a biocompatible prepolymer and, when so used, the presence of the biocompatible solvent becomes optional. In this embodiment, this invention is directed to a composition comprising: [0049]
[0050] (a) a biocompatible prepolymer; [0050]
[0051] (b) an optional biocompatible solvent; and [0051]
[0052] (c) from about 0.1 to about 25 weight percent of a water insoluble radioisotope having a radioactive content of from about 0.5 microcurie to about 100 millicurie. [0052]
[0053] In addition, this invention is also directed to a method for embolizing a blood vessel leading to or in a solid mass tumor in a mammal and causing necrosis to a portion of said solid mass tumor which method comprises: [0053]
[0054] (a) identifying a blood vessel in said mammal which leads to or is in the solid mass tumor; [0054]
[0055] (b) injecting a sufficient amount of an embolic composition comprising a biocompatible prepolymer, a water insoluble radioisotope and optionally a biocompatible solvent into said blood vessel under conditions wherein the prepolymer polymerizes to form a solid mass which embolizes the blood vessel and further wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of the tumor, [0055]
[0056] wherein said delivery is conducted under conditions wherein said prepolymer polymerizes in situ, in the presence of the water insoluble contrast agent, at the vascular site thereby embolizing the blood vessel. [0056]
[0057] In a preferred embodiment, the biocompatible solvent is dimethylsulfoxide (DMSO), ethanol or acetone. [0057]
[0058] In one embodiment, the radioisotope acts as a contrast agent to permit visualization of the composition during catheter delivery. Alternatively, a non-radioactive contrast agent is employed in combination with the radioisotope in order to ensure visualization. [0058] DETAILED DESCRIPTION OF THE INVENTION
[0059] This invention is directed to novel compositions which are particularly suitable for treating solid mass tumors via delivery of the composition either directly to the solid mass tumor or to a vascular site leading to or in the solid mass tumor and subsequent embolization of this vascular site while, in either case, delivering a therapeutically effective amount of radiation to the solid mass tumor. [0059]
[0060] However, prior to discussing this invention in further detail, the following terms will first be defined: [0060]
[0061] The term “embolizing” as used in conjunction with “embolizing compositions” and “embolizing agents” refers to a process wherein a material is injected into a blood vessel which thereafter fills or plugs the blood vessel so that blood flow through the vessel ceases. [0061]
[0062] Embolization is used to ablate diseased tissue (e.g., tumors, etc.) by cutting off its blood supply. Traditionally, in the case of, for example, tumors, catheter embolization is used to induce necrosis of the tumor by obstructing its arterial supply. Needles may also be used to inject the embolic compositions of this invention into the appropriate vascular sites as well as directly into the solid tumor mass. Embolization may entail deliberate sacrifice of the organ harboring the tumor, as in embolization of renal cancers. However, in the liver with its dual blood supply, a tumor can be embolized through the hepatic artery while the normal hepatic parenchyma is sustained by portal venous inflow. [0062]
[0063] The term “solid mass tumor” refers to cancerous and non-cancerous conditions manifested by a solid mass growth as opposed to conditions lacking such a solid mass growth, e.g., leukemia. Various types of solid mass tumors may be treated with the compositions and methods of this invention including both cancerous and benign tumors. Examples of cancerous solid mass tumors include, for instance, lung cancer, cervical cancer, soft tissue sarcomas, and kidney and liver tumors. Examples of benign tumors include benign brain tumors, uterine fibroid tumors, and the like. [0063]
[0064] The term “biocompatible polymer” refers to polymers which, in the amounts employed, are non-toxic and substantially non-immunogenic when used internally in the patient and which are substantially insoluble in blood. The biocompatible polymer can be either biodegradable or, preferably, non-biodegradable. [0064]
[0065] Biodegradable polymers are disclosed in the art.[0065] ^16,18 For example, Dunn, et al.¹⁶ discloses the following examples of biodegradable polymers: linear-chain polymers such as polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, and copolymers, terpolymers and combinations thereof. Other biodegradable polymers include, for example, gelatin, collagen, etc.¹⁸
[0066] Suitable non-biodegradable biocompatible polymers include, by way of example, cellulose acetates[0066] ^2,6-7 (including cellulose diacetate⁵), ethylene vinyl alcohol copolymers^4,8, hydrogels (e.g., acrylics), polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof⁹.
[0067] Preferably, the biocompatible polymer employed does not cause an adverse inflammatory reaction when employed in vivo. The particular biocompatible polymer employed is selected relative to the viscosity of the resulting polymer solution, the solubility of the biocompatible polymer in the biocompatible solvent, and the like. For example, the selected biocompatible polymer should be soluble in the amounts employed in the selected biocompatible solvent and the resulting composition should have a viscosity suitable for in vivo delivery either by catheter or by injection. Such factors are well within the skill of the art. [0067]
[0068] Preferred biocompatible polymers include cellulose diacetate and ethylene vinyl alcohol copolymer. Cellulose diacetate polymers are either commercially available or can be prepared by art recognized procedures. In a preferred embodiment, the number average molecular weight, as determined by gel permeation chromatography, of the cellulose diacetate composition is from about 25,000 to about 100,000 more preferably from about 50,000 to about 75,000 and still more preferably from about 58,000 to 64,000. The weight average molecular weight of the cellulose diacetate composition, as determined by gel permeation chromatography, is preferably from about 50,000 to 200,000 and more preferably from about 100,000 to about 180,000. As is apparent to one skilled in the art, with all other factors being equal, cellulose diacetate polymers having a lower molecular weight will impart a lower viscosity to the composition as compared to higher molecular weight polymers. Accordingly, adjustment of the viscosity of the composition can be readily achieved by merely adjusting the molecular weight of the polymer composition. [0068]
[0069] Ethylene vinyl alcohol copolymers comprise residues of both ethylene and vinyl alcohol monomers. Small amounts (e.g., less than 5 mole percent) of additional monomers can be included in the polymer structure or grafted thereon provided such additional monomers do not alter the embolizing properties of the composition. Such additional monomers include, by way of example only, maleic anhydride, styrene, propylene, acrylic acid, vinyl acetate and the like. [0069]
[0070] Ethylene vinyl alcohol copolymers are either commercially available or can be prepared by art recognized procedures. Preferably, the ethylene vinyl alcohol copolymer composition is selected such that a solution of 5 weight percent of the ethylene vinyl alcohol copolymer, 20 weight percent of a tantalum contrast agent in DMSO has a viscosity equal to or less than 60 centipoise at 20° C. As is apparent to one skilled in the art, with all other facts being equal, copolymers having a lower molecular weight will impart a lower viscosity to the composition as compared to higher molecular weight copolymers. Accordingly, adjustment of the viscosity of the composition as necessary for catheter delivery can be readily achieved by merely adjusting the molecular weight of the copolymer composition. [0070]
[0071] As is also apparent, the ratio of ethylene to vinyl alcohol in the copolymer affects the overall hydrophobicity/hydrophilicity of the composition which, in turn, affects the relative water solubility/insolubility of the composition as well as the rate of precipitation of the copolymer in an aqueous environment (e.g., blood or tissue). In a particularly preferred embodiment, the copolymers employed herein comprise a mole percent of ethylene of from about 25 to about 60 and a mole percent of vinyl alcohol of from about 40 to about 75. These compositions provide for requisite precipitation rates suitable for use in embolizing blood vessels. [0071]
[0072] The term “contrast agent” refers to a biocompatible radiopaque material capable of being monitored during injection into a mammalian subject by, for example, radiography. The contrast agent can be either water soluble or water insoluble and preferably does not contain radioactivity above the native or endogenous amounts naturally occurring in the elements employed (i.e., are “non-radioactive”). [0072]
[0073] Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine. Examples of water insoluble contrast agents include tantalum, tantalum oxide, and barium sulfate, each of which is commercially available in the proper form for in vivo use including a preferred particle size of about 10 μm or less. Other water insoluble contrast agents include gold, tungsten, and platinum powders. [0073]
[0074] Preferably, the contrast agent is water insoluble (i.e., has a water solubility of less than 0.01 mg/ml at 20° C.). [0074]
[0075] The term “biocompatible solvent” refers to an organic material liquid at least at body temperature of the mammal in which the biocompatible polymer is soluble and, in the amounts used, is substantially non-toxic. Suitable biocompatible solvents include, by way of example, dimethylsulfoxide, analogues/homologues of dimethylsulfoxide, ethanol, acetone, and the like. Aqueous mixtures with the biocompatible solvent can also be employed provided that the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood. Preferably, the biocompatible solvent is dimethylsulfoxide. [0075]
[0076] The term “encapsulation” as used relative to the contrast agent being encapsulated in the polymer precipitate is not meant to infer any physical entrapment of the contrast agent within the precipitate much as a capsule encapsulates a medicament. Rather, this term is used to mean that an integral coherent precipitate forms which does not separate into individual components. [0076]
[0077] The term “biocompatible prepolymer” refers to materials which polymerize in situ to form a polymer and which, in the amounts employed, are non-toxic and substantially non-immunogenic when used internally in the patient and which are substantially insoluble in blood. Suitable biocompatible prepolymers include, by way of example, cyanoacrylates[0077] ^10,11,12, (C1-C6)hydroxyalkyl (C1-C6)alkacrylate (e.g., hydroxyethyl methacrylate), silicon prepolymers, and the like. The prepolymer can either be a monomer or a reactive oligomer¹². Preferably, the biocompatible prepolymer does not cause an adverse inflammatory reaction when employed in vivo.
[0078] The term “radioisotope” refers to naturally or non-naturally occurring water insoluble radioisotopes conventionally employed in nuclear medicine including, by way of example only, [0078] ⁹⁰yttrium, ¹⁹²iridium, ¹⁹⁸gold, ¹²⁵iodine, ¹³⁷cesium, ⁶⁰cobalt, ⁵⁵cobalt, ⁵⁶cobalt, ⁵⁷cobalt, ⁵²magnesium, ⁵⁵iron, ³²phosphorus, and ⁹⁰strontium. Other radionuclides currently being produced for use in nuclear medicine include, for example, ⁸¹rubidium, ²⁰⁶bismuth, ⁶⁷gallium, ⁷⁷bromine, ¹²⁹cesium, ⁷³selenium, ⁷²selenium, ⁷²arsenic, ¹⁰³palladium, ²⁰³lead, ¹¹¹indium, ⁵²iron, ¹⁶⁷thulium, ⁵⁷nickel, 62zinc, ⁶¹copper, ²⁰¹thallium, and ¹²³iodine. Each of these isotopes can be made by standard techniques well known in the art¹³. Additionally, radioisotopes which are water soluble or water reactable are typically used as water insoluble salts.
[0079] In one embodiment, radioisotopes having a sufficiently high atomic number so as to be radiopaque can be used to serve both as a source of radiation and as a water insoluble contrast agent for detection under fluoroscopy. [0079]
[0080] In another embodiment, a separate non-radioactive contrast agent is employed in conjunction with the radioisotope. [0080]
[0081] The term “absorbed dose” or “radiation dose” refers to the dose of radiation typically employed by the attending oncologist in treating solid mass tumors. The radiation dose is defined in terms of energy deposited per unit mass, given in the following units: 1 Gray (Gy)=1 Joule per kilogram. In the past, the standard unit of radiotherapy was 1 rad, and 1 Gy=100 rads. [0081]
[0082] Compositions [0082]
[0083] The polymer or prepolymer compositions employed in the methods of this invention are prepared by conventional methods whereby each of the components is added and the resulting composition mixed together until the overall composition is substantially homogeneous. [0083]
[0084] For example, polymer compositions can be prepared by adding sufficient amounts of the biocompatible polymer to the biocompatible solvent to achieve the effective concentration for the polymer composition. Preferably, the polymer composition will comprise from about 2.5 to about 8.0 weight percent of the biocompatible polymer composition based on the total weight of the polymer composition and more preferably from about 4 to about 5.2 weight percent. If necessary, gentle heating and stirring can be used to effect dissolution of the biocompatible polymer into the biocompatible solvent, e.g., 12 hours at 50° C. [0084]
[0085] Where a separate non-radioactive contrast agent is employed, sufficient amounts of this contrast agent are then added to the biocompatible solvent to achieve the effective concentration for the complete composition. Preferably, the composition will comprise from about 7 to about 40 weight percent of total contrast agent (non-radioactive contrast agent plus any radiopaque radioisotope) and more preferably from 5 about 14 to about 30 weight percent and even more preferably about 22 weight percent. [0085]
[0086] When a water soluble non-radioactive contrast agent is employed, the agent is typically soluble in the solution comprising the non-aqueous solvent and stirring is effected to render the composition homogeneous. [0086]
[0087] When a water insoluble non-radioactive contrast agent is employed, the agent is insoluble in the biocompatible solvent, and stirring is employed to effect homogeneity of the resulting suspension. In order to enhance formation of the suspension, the particle size of the water insoluble non-radioactive contrast agent is preferably maintained at about 10 μm or less and more preferably at from about 1 to about 5 μm (e.g., an average size of about 2 μm). [0087]
[0088] In one embodiment, a non-radioactive contrast agent having a particle size of less than 10 μm is prepared, for example, by fractionation. In such an embodiment, a non-radioactive water insoluble contrast agent such as tantalum, having an average particle size of less than about 20 μm, is added to an organic liquid such as ethanol (absolute) preferably in a clean environment. Agitation of the resulting suspension followed by settling for approximately 40 seconds permits the larger particles to settle faster. Removal of the upper portion of the organic liquid followed by separation of the liquid from the particles results in a reduction of the particle size which is confirmed under an optical microscope. The process is optionally repeated until a desired average particle size is reached. [0088]
[0089] The particular order of addition of components to the biocompatible solvent is not critical and stirring of the resulting suspension is conducted as necessary to achieve homogeneity of the composition. Preferably, mixing/stirring of the composition is conducted under an anhydrous atmosphere at ambient pressure. The resulting composition can be heat sterilized and then stored preferably in sealed bottles or vials (e.g., amber bottles) until needed. [0089]
[0090] Each of the polymers recited herein is commercially available or can be prepared by methods well known in the art. For example, polymers are typically prepared by conventional techniques such as radical, thermal, UV, γ irradiation, or electron beam induced polymerization employing, as necessary, a polymerization catalyst or polymerization initiator to provide for the polymer composition. The specific manner of polymerization is not critical and the polymerization techniques employed do not form a part of this invention. [0090]
[0091] In order to maintain solubility in the biocompatible solvent, the polymers described herein are preferably not cross-linked. [0091]
[0092] Prepolymer compositions can be prepared by adding sufficient amounts of any non-radioactive contrast agent employed in the liquid (e.g., liquid prepolymer) to achieve the effective concentration for the complete polymer composition. Preferably, the total contrast agent (non-radioactive contrast agent plus any radiopaque radioisotope) will comprise from about 7 to about 40 weight percent of the prepolymer composition based on the total weight of the composition and more preferably from about 14 to about 30 weight percent and even more preferably about 22 weight percent. [0092]
[0093] When a non-radioactive contrast agent is used which is not soluble in the biocompatible prepolymer composition, stirring is employed to effect homogeneity of the resulting suspension. In order to enhance formation of the suspension, the particle size of the insoluble non-radioactive contrast agent is preferably maintained at about 10 μm or less and more preferably at from about 1 to about μm (e.g., an average size of about 2 μm). [0093]
[0094] When the prepolymer is liquid (as in the case of cyanoacrylates or silicone), the use of a biocompatible solvent is not strictly necessary but may be preferred to provide for an appropriate viscosity, for an appropriate curing time, etc. in the embolic composition. Preferably, when employed, the biocompatible solvent will comprise from about 30 to about 90 weight percent of the biocompatible prepolymer composition based on the total weight of the prepolymer composition and more preferably from about 60 to about 80 weight percent. When a biocompatible solvent is employed, the prepolymeric composition typically comprises from about 10 to about 50 weight percent of the prepolymer based on the total weight of the composition. [0094]
[0095] Suitable solvents include iodinated soy bean or poppy seed oil for cyanoacrylates and water for hydroxyacrylics such as hydroxyethyl methacrylate. In such cases, the oil acts both as a carrier for the prepolymer, a contrast agent and a polymerization time modifier. Other solvents include hexamethyldisiloxane which is preferably employed in conjunction with silicone. [0095]
[0096] In a particularly preferred embodiment, the prepolymer is cyanoacrylate which is preferably employed in the absence of a biocompatible solvent. When so employed, the cyanoacrylate adhesive is selected to have a viscosity of from about 5 to about 20 centipoise at 20° C. [0096]
[0097] The radioisotope is preferably added to the otherwise complete composition immediately prior to the administration of the composition to the patient in order to reduce exposure of radiation to the clinician. In a preferred embodiment, the radioisotope is [0097] ¹⁹²iridium, ¹⁹⁸gold, ¹²⁵iodine, ¹³⁷cesium or ⁶⁰cobalt. The radioisotope is preferably selected relative to the type and size of the solid mass tumor and its location in the patient. This material may also be used as part of or the entire contrast agent to aid in the placement of the composition to cause necrosis to at least a portion of the tumor.
[0098] Treatment dosages of radiation employed in a particular patient are, of course, dependent upon the judgment of the attending clinician and nuclear medicine professional depending upon factors such as the type and severity of the solid mass tumor in the patient, the age, weight and general condition of the patient, the toxicity and/or side effects due to the radiation treatment and the like. Such factors are well known to the skilled artisan. In some cases, it may be necessary or desirable only to embolize and necrosis blood vessel(s) leading to or located in the solid mass tumors and, accordingly, appropriate radiation levels are selected relative to such a result. [0098]
[0099] Preferably, however, the composition is employed to both embolize the blood vessel and to cause necrosis of at least a portion of the tumor. When so employed, appropriate radiation levels are selected to effect such a result. While there is no consensus on the ideal radiotherapy prescription for a particular tumor type, a number of prescriptions are currently used based either on the principle of administering a high dose which requires multiple fractions over a relatively long time or short treatment time in relatively large fractions. For example, 64 Gy in 32 fractions over 6.5 weeks or 52 Gy in 15 fractions over 3 weeks. Appropriate prescription is based on an assessment of the individual tumor. [0099]
[0100] In any event, in this embodiment, sufficient levels of radiation are employed to effect necrosis of at least part of the tumor. [0100]
[0101] In view of the above, the compositions described herein comprise from about 0.1 to about 25 weight percent of a water insoluble radioisotope having from a radioactive content of from about 0.5 microcurie to about 100 millicurie. In a preferred embodiment, the amount and radioactive content of the radioisotope is sufficient to provide for a cumulative ionizing radiation dosage at the site of implantation in a mammalian subject of from about 200 to 10,000 rads [2 to 100 Gray (Gy)]. [0101]
[0102] The embolic compositions of this invention may be permanent or temporarily placed within the patient, depending upon an assessment of the tumor. If a temporary implant is warranted, a biodegradable polymer can be used which, over time, will leave only remnants of the radioactive material. Alternatively, a biodegradable or non-biodegradable polymer can be used wherein the resulting precipitate is subsequently removed from the patient, e.g., with a biocompatible solvent and catheter device. For example, during removal, a catheter is placed adjacent the polymer precipitate in the embolized vascular site. A biocompatible solvent such as DMSO is delivered to the vascular site from the catheter lumen under conditions such that the polymer precipitate dissolves in the biocompatible solvent. If desired, a second lumen in the catheter can be used to removed the resulting solution. [0102]
[0103] In such reversible placement of the radioactive embolizing compositions, the use of a water insoluble contrast agent is highly preferred because it allows the clinician to accurately visualize the position of the embolizing plug in vivo. Once visualized, the clinician can direct the tip of a microcatheter to this position and remove the plug in the manner described above. [0103]
[0104] Alternatively, a non-biodegradable polymer can be used and the polymer composition can be removed surgically along with any necrotic tissue and remaining tumor tissue. [0104]
[0105] Methods [0105]
[0106] The compositions described above can be employed in the treatment of solid mass tumors. In one such treatment, these compositions are employed in methods for the needle or catheter assisted embolization of mammalian blood vessels. The injection of the embolic composition may be performed intraoperatively or percutaneously. In such methods, a sufficient amount of this composition is introduced into the selected blood vessel via a needle or catheter delivery means under fluoroscopy so that upon precipitation of the polymer or polymerization of the prepolymer, the blood vessel is embolized. The particular amount of embolizing composition employed is dictated by the total volume of the vasculature to be embolized, the concentration of polymer/prepolymer in the composition, the rate of precipitation (solids formation) of the polymer, etc., and the total level of radiation to be delivered. [0106]
[0107] A particularly preferred method is catheter delivery of the embolizing compositions of this invention to the selected vascular site via a small diameter medical catheter. The particular catheter employed is not critical provided that polymeric catheter components are compatible with the embolizing composition (i.e., the catheter components will not readily degrade in the embolizing composition) and the catheter can be placed at the selected vascular site. In this regard, it is preferred to use polyethylene in the catheter components because of its inertness in the presence of the embolizing composition described herein. Other materials compatible with the embolizing compositions can be readily determined by the skilled artisan and include, for example, other polyolefins, fluoropolymers (e.g., Teflon™), silicone, etc. [0107]
[0108] When the polymeric composition is introduced in vivo, the biocompatible solvent diffuses rapidly into the body fluid and a solid, non-migratory precipitate forms which precipitate is the water insoluble polymer and radioisotope encapsulated therein as well as any non-radioactive water insoluble contrast agent. Without being limited to any theory, it is believed that initially, a soft gel to spongy solid precipitate forms upon contact with the body fluid. When this composition is introduced into a vascular site, the resulting precipitate restricts blood flow, entrapping red cells thereby causing clot embolization of the blood vessel. [0108]
[0109] When a prepolymeric composition is introduced in vivo, the prepolymer rapidly polymerizes in situ (less than 5 minutes) and a solid non-migratory mass forms which mass is the water insoluble polymer and radioisotope encapsulated therein as well as any non-radioactive water insoluble contrast agent. When this composition is introduced into a vascular site, the resulting mass restricts blood flow, entrapping red cells thereby causing clot embolization of the blood vessel. [0109]
[0110] In another method, the compositions of this invention can also be directly injected into a solid mass tumor by, e.g., needle delivery techniques wherein a sufficient amount of radiation is incorporated into the composition via the radioactive isotope to ablate at least a portion of the solid mass tumor. [0110]
[0111] Utility [0111]
[0112] The compositions described herein are useful in the necrosis of solid mass tumors by, for example, embolization of blood vessels leading to or in the solid mass tumor. When employed to embolized blood vessels, it is preferred that the level of radiation employed in the composition is sufficient to also ablate at least a portion of solid mass tumors. Accordingly, these compositions find use in human and other mammalian subjects requiring treatment. [0112]
[0113] Alternatively, the compositions can be delivered directly into the solid mass tumor and the radiation contained therein can be employed to effect necrosis of the tumor. [0113]
[0114] It is contemplated that these compositions can also be employed as a carrier for a chemotherapeutic agent wherein this agent is delivered in vivo for subsequent release to the solid mass tumor. Such chemotherapeutic agents are well known in the art and, include by way of example only, fluorouracil, methotrexate, cisplatin and the like. A pharmaceutical agent such as an anti-inflammatory agent, an antibiotic, and the like can be employed either in combination with the chemotherapeutic agent or as an alternative thereto. [0114]
[0115] The following examples are set forth to illustrate the claimed invention and are not to be construed as a limitation thereof. [0115] EXAMPLES
[0116] Unless otherwise stated, all temperatures are in degrees Celsius. Also, in these examples and elsewhere, the following abbreviations have the following meanings: [0116] cc = cubic centimeter cm = centimeter DMSO = dimethylsulfoxide EVOH = ethylene vinyl alcohol copolymer g = gram Gy = gray (units for dose of radiation; 1 Gy = 1 J per kg = 100 rads) ID = internal diameter in. = inch J = joule kg = kilogram mg = milligram min. = minute mL = milliliter mm = millimeter OD = outer diameter sec. = seconds μm = micron Example 1
[0117] The purpose of this example is to demonstrate the preparation of polymer compositions useful in this invention. These compositions were prepared using “cold” isotopes in order to illustrate the compatibility of the compositions and suitability for delivery in vivo. It is understood that “hot” compositions could be similarly prepared. [0117]
[0118] Specifically, an EVOH polymer composition was prepared as follows: [0118]
[0119] Composition [0119]
[0120] A) 0.396 gm EVOH (48 mole percent ethylene); [0120]
[0121] B) 1.485 gm micronized tantalum; and [0121]
[0122] C) 4.95 mL DMSO. [0122]
[0123] After dissolution of the polymer at 50° C., 3 cc of this composition was then added to 0.03 g iridium powder (0.4% by weight) and the resulting composition was shaken for 4 minutes to disperse the insoluble materials. Immediately, 0.8 cc of the suspension was withdrawn via a 1 cc syringe through a 21 gauge needle. Three 0.1 cc aliquots were then injected into an excess of normal saline maintained at about 37° C. to generate the precipitate. The saline was then stirred for about 10 minutes whereupon the precipitate was examined for inner/outer consistency. In each case, a solid coherent precipitate formed in the saline. [0123]
[0124] The procedure set forth above was repeated twice. In the first instance, the amount of tantalum powder was changed to 14 weight percent and the amount of iridium powder was increased to 6 weight percent. In the second instance, the tantalum powder was removed from the composition and the amount of iridium adjusted to 20 weight percent. In each case, the total amount of tantalum/iridium was about 20 weight percent. [0124]
[0125] Both compositions, upon injection into saline, provided a solid coherent precipitate. [0125] Example 2
[0126] The purpose of this example is to demonstrate the preparation of a prepolymer composition useful in this invention. This compositions was prepared using “cold” isotopes in order to illustrate the compatibility of the composition and suitability for delivery in vivo. It is understood that “hot” compositions could be similarly prepared. [0126]
[0127] Specifically, a cyanoacrylate-prepolymer composition was prepared by adding 500 mg of iridium non-radioactive powder (Aldrich 20968-6, 99.9% purity, screened to <25 μm) to 2 g n-butyl cyanoacrylate containing 100 ppm SO[0127] ₂ as a stabilizer to yield a composition comprising 20% by weight of iridium. The ingredients mixed well, yielding a black/gray suspension. The iridium settled within several seconds after mixing, so constant, gentle agitation was required. In this regard, a higher viscosity cyanoacrylate composition could be used to prolong the suspension time of the iridium or, alternatively, a smaller particle size of the iridium can be used.
[0128] The mixture remained liquid with no signs of premature polymerization when evaluated at one hour after mixing and again after 12 days thereby evidencing that the iridium was compatible in this composition. [0128]
[0129] About 0.2 cc of this composition was taken up in a 1 cc syringe through a 21 gage needle and injected into about 150 cc of a 0.1 N NaHCO[0129] ₃ aqueous solution to simulate a blood environment and cure the prepolymer. Upon injection, three small black/gray droplets were formed which immediately fell to the bottom of the container. It took about 15 minutes for the cyanoacrylate to fully cure and to be tack free.
[0130] The procedure set forth above was repeated with cyanoacrylate alone (i.e., without the iridium) and the cyanoacrylate cured in approximately the same time evidencing that the iridium was compatible with the cyanoacrylate. [0130] Example 3
[0131] The purpose of this example is to illustrate how to conduct embolization of mammalian blood vessels leading to solid mass tumors via the methods of this invention. This example employs a rabbit with a solid mass tumor located in the upper thigh. [0131]
[0132] Specifically, a healthy male rabbit (4 kg) is implanted with cells for the VX2 tumor. After one week maturation, the tumor will have recruited blood supply from the deep femoral artery and will be about 1 cc. At this time, embolization of the tumor is conducted from a carotid artery cut down and catherization of the deep femoral artery with a 3 Fr Cook polyethylene catheter. Catheter placement is about two cm or less proximal of the tumor feed branch. The artery is then embolized by injection of sufficient amount of the 0.4% iridium composition described in Example 1 except that the iridium has a radioactive content of 150 μCi. Upon introduction at the vascular site, a solid coherent precipitate forms which comprises the polymer, the contrast agent and the iridium which precipitate embolizes the blood vessel. Over 30 days, the amount of radiation delivered internally to the rabbit is about 25 Gray and the necrotic tumor and surrounding tissue are excised for examination. [0132]
[0133] In an optional embodiment, a two lumen catheter can be reintroduced into the femoral artery and placed adjacent to the precipitate. DMSO is introduced via a first lumen whereupon the precipitate is dissolved. The second lumen is employed to remove at least a portion of the DMSO/dissolved precipitate from the vascular site by aspiration. [0133]
[0134] From the foregoing description, various modifications and changes in the composition and method will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein. [0134]

权利要求:
Claims (49)
[1" id="US-20010009656-A1-CLM-00001] 1. A composition suitable for treating a solid mass tumor in a mammal which composition comprises:
(a) a biocompatible polymer;
(b) a biocompatible solvent; and
(c) from about 0.1 to about 25 weight percent of a water insoluble radioisotope having from a radioactive content of from about 0.5 microcurie to about 100 millicuries.
[2" id="US-20010009656-A1-CLM-00002] 2. The composition according to
claim 1 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol and acetone.
[3" id="US-20010009656-A1-CLM-00003] 3. The composition according to
claim 2 wherein said biocompatible solvent is dimethylsulfoxide.
[4" id="US-20010009656-A1-CLM-00004] 4. The composition according to
claim 1 wherein said water insoluble biocompatible polymer is selected from the group consisting of biodegradable and non-biodegradable polymers.
[5" id="US-20010009656-A1-CLM-00005] 5. The composition according to
claim 4 wherein said biocompatible polymer is non-biodegradable.
[6" id="US-20010009656-A1-CLM-00006] 6. The composition according to
claim 5 wherein said non-biodegradable biocompatible polymer is selected from the group consisting of cellulose acetates, ethylene vinyl alcohol copolymers, hydrogels, polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.
[7" id="US-20010009656-A1-CLM-00007] 7. The composition according to
claim 6 wherein said non-biodegradable biocompatible polymer is a copolymer of ethylene and vinyl alcohol.
[8" id="US-20010009656-A1-CLM-00008] 8. The composition according to
claim 4 wherein said biocompatible polymer is biodegradable.
[9" id="US-20010009656-A1-CLM-00009] 9. The composition according to
claim 8 wherein said biodegradable biocompatible polymer is a linear-chain polymer selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, copolymers, terpolymers thereof, gelatin, and collagen.
[10" id="US-20010009656-A1-CLM-00010] 10. The composition according to
claim 1 wherein said radioisotope is selected from the group consisting of ⁹⁰yttrium, ¹⁹²iridium, ¹⁹⁸gold, ¹²⁵iodine, ¹³⁷cesium, ⁶⁰cobalt, ⁵⁵cobalt, ⁵⁶cobalt, ⁵⁷cobalt, ⁵⁷magnesium, ⁵⁵iron, ³²phosphorus, ⁹⁰strontium, ⁸¹rubidium, ²⁰⁶bismuth, ⁶⁷gallium, ⁷⁷bromine, ¹²⁹cesium, ⁷³selenium, ⁷²selenium, ⁷²arsenic, ¹⁰³palladium, ²⁰³lead, ¹¹¹indium, ⁵²iron, ¹⁶⁷thulium, ⁵⁷nickel, ⁶²zinc, ⁶¹copper, ²⁰¹thallium, and ¹²³iodine.
[11" id="US-20010009656-A1-CLM-00011] 11. The composition according to
claim 1 which further comprises a non-radioactive contrast agent.
[12" id="US-20010009656-A1-CLM-00012] 12. The composition according to
claim 11 wherein said non-radioactive contrast agent is water soluble.
[13" id="US-20010009656-A1-CLM-00013] 13. The composition according to
claim 12 wherein said water soluble non-radioactive contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
[14" id="US-20010009656-A1-CLM-00014] 14. The composition according to
claim 11 wherein said non-radioactive contrast agent is water insoluble.
[15" id="US-20010009656-A1-CLM-00015] 15. The composition according to
claim 14 wherein said water insoluble contrast agent is tantalum, tantalum oxide, barium sulfate, tungsten, gold and platinum.
[16" id="US-20010009656-A1-CLM-00016] 16. A method for embolizing a blood vessel leading to or in a solid mass tumor in a mammal and causing necrosis to a portion of said solid mass tumor which method comprises:
(a) identifying a blood vessel in said mammal which leads to or is in the solid mass tumor;
(b) injecting a sufficient amount of an embolic composition comprising a biocompatible polymer, a biocompatible solvent and a water insoluble radioisotope into said blood vessel under conditions wherein a precipitate is formed which embolizes the blood vessel and further wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of said tumor.
[17" id="US-20010009656-A1-CLM-00017] 17. The method according to
claim 16 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol and acetone.
[18" id="US-20010009656-A1-CLM-00018] 18. The method according to
claim 17 wherein said biocompatible solvent is dimethylsulfoxide.
[19" id="US-20010009656-A1-CLM-00019] 19. The method according to
claim 16 wherein said water insoluble biocompatible polymer is selected from the group consisting of biodegradable and non-biodegradable polymers.
[20" id="US-20010009656-A1-CLM-00020] 20. The method according to
claim 19 wherein said biocompatible polymer is non-biodegradable.
[21" id="US-20010009656-A1-CLM-00021] 21. The method according to
claim 20 wherein said non-biodegradable biocompatible polymer is selected from the group consisting of cellulose acetates, ethylene vinyl alcohol copolymers, hydrogels, polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.
[22" id="US-20010009656-A1-CLM-00022] 22. The method according to
claim 21 wherein said non-biodegradable biocompatible polymer is a copolymer of ethylene and vinyl alcohol.
[23" id="US-20010009656-A1-CLM-00023] 23. The method according to
claim 19 wherein said biocompatible polymer is biodegradable.
[24" id="US-20010009656-A1-CLM-00024] 24. The method according to
claim 23 wherein said biodegradable biocompatible polymer is a linear-chain polymer selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, copolymers, terpolymers thereof, gelatin and collagen.
[25" id="US-20010009656-A1-CLM-00025] 24. The method according to
claim 16 wherein said radioisotope is selected from the group consisting of ⁹⁰yttrium, ¹⁹²iridium, ¹⁹⁸gold, ¹²⁵iodine, ¹³⁷cesium, ⁶⁰cobalt, ⁵⁵cobalt, ⁵⁶cobalt, ⁵⁷cobalt, ⁵⁷magnesium, ⁵⁵iron, ³²phosphorus, ⁹⁰strontium, ⁸¹rubidium, ²⁰⁶bismuth, ⁶⁷gallium, ⁷⁷bromine, ¹²⁹cesium, ⁷³selenium, ⁷²selenium, ⁷²arsenic, ¹⁰³palladium, 203lead, ¹¹¹indium, ⁵²iron, ¹⁶⁷thulium, ⁵⁷nickel, ⁶²zinc, ⁶¹copper, ²⁰¹thallium, and ¹²³iodine.
[26" id="US-20010009656-A1-CLM-00026] 25. The method according to
claim 16 wherein said composition further comprises a non-radioactive contrast agent.
[27" id="US-20010009656-A1-CLM-00027] 26. The method according to
claim 25 wherein said non-radioactive contrast agent is water soluble.
[28" id="US-20010009656-A1-CLM-00028] 27. The method according to
claim 26 wherein said water soluble non-radioactive contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
[29" id="US-20010009656-A1-CLM-00029] 28. The method according to
claim 25 wherein said non-radioactive contrast agent is water insoluble.
[30" id="US-20010009656-A1-CLM-00030] 29. The method according to
claim 28 wherein said water insoluble contrast agent is tantalum, tantalum oxide, barium sulfate, tungsten, gold and platinum.
[31" id="US-20010009656-A1-CLM-00031] 30. A composition suitable for treating a solid mass tumor in a mammal which composition comprises:
(a) a biocompatible prepolymer;
(b) an optional biocompatible solvent; and
(c) from about 0.1 to about 25 weight percent of a water insoluble radioisotope having from a radioactive content of from about 0.5 microcurie to about 100 millicurie.
[32" id="US-20010009656-A1-CLM-00032] 31. The composition according to
claim 30 wherein said biocompatible prepolymer is selected from the group consisting of cyanoacrylates, (C1-C6)hydroxyalkyl (C1-C6)alkacrylate, and silicone prepolymers.
[33" id="US-20010009656-A1-CLM-00033] 32. The composition according to
claim 31 wherein said biocompatible prepolymer is a cyanoacrylate.
[34" id="US-20010009656-A1-CLM-00034] 33. The composition according to
claim 30 wherein said radioisotope is selected from the group consisting of ⁹⁰yttrium, ¹⁹²iridium, ¹⁹⁸gold, ¹²⁵iodine, ¹³⁷cesium, ⁶⁰cobalt, ⁵⁵cobalt, ⁵⁶cobalt, ⁵⁷cobalt, ⁵⁷magnesium, ⁵⁵iron, ³²phosphorus, ⁹⁰strontium, ⁸¹rubidium, ²⁰⁶bismuth, ⁶⁷gallium, ⁷⁷bromine, ¹²⁹cesium, ⁷³selenium, ⁷²selenium, ⁷²arsenic, ¹⁰³palladium, ²⁰³lead, ¹¹¹indium, ⁵²iron, ¹⁶⁷thulium, ⁵⁷nickel, ⁶²zinc, ⁶¹copper, ²⁰¹thallium, and ¹²³iodine.
[35" id="US-20010009656-A1-CLM-00035] 34. The composition according to
claim 30 which further comprises a non-radioactive contrast agent.
[36" id="US-20010009656-A1-CLM-00036] 35. The composition according to
claim 34 wherein said non-radioactive contrast agent is water soluble.
[37" id="US-20010009656-A1-CLM-00037] 36. The composition according to
claim 35 wherein said water soluble non-radioactive contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
[38" id="US-20010009656-A1-CLM-00038] 37. The composition according to
claim 34 wherein said non-radioactive contrast agent is water insoluble.
[39" id="US-20010009656-A1-CLM-00039] 38. The composition according to
claim 37 wherein said water insoluble contrast agent is tantalum, tantalum oxide, barium sulfate, tungsten, gold and platinum.
[40" id="US-20010009656-A1-CLM-00040] 39. A method for embolizing a blood vessel leading to or in a solid mass tumor in a mammal and causing necrosis to a portion of said solid mass tumor which method comprises:
(a) identifying a blood vessel in said mammal which leads to or is in the solid mass tumor;
(b) injecting a sufficient amount of an embolic composition comprising a biocompatible prepolymer, a water insoluble radioisotope and optionally a biocompatible solvent into said blood vessel under conditions wherein the prepolymer polymerizes and forms a solid mass which embolizes the blood vessel and further wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of the tumor,
wherein said delivery is conducted under conditions wherein said prepolymer polymerizes in situ, in the presence of the water insoluble contrast agent, at the vascular site thereby embolizing the blood vessel.
[41" id="US-20010009656-A1-CLM-00041] 40. The method according to
claim 39 wherein said biocompatible prepolymer is selected from the group consisting of cyanoacrylates, (C1-C6)hydroxyalkyl (C1-C6)alkacrylate, and silicone prepolymers.
[42" id="US-20010009656-A1-CLM-00042] 41. The method according to
claim 40 wherein said biocompatible prepolymer is a cyanoacrylate.
[43" id="US-20010009656-A1-CLM-00043] 42. The method according to
claim 39 wherein said radioisotope is selected from the group consisting of ⁹⁰yttrium, ¹⁹²iridium, ¹⁹⁸gold, ¹²⁵iodine, ¹³⁷cesium, ⁶⁰cobalt, ⁵⁵cobalt, ⁵⁶cobalt, ⁵⁷cobalt, ⁵⁷magnesium, ⁵⁵iron, ³²phosphorus, ⁹⁰strontium, ⁸¹rubidium, ²⁰⁶bismuth, ⁶⁷gallium, ⁷⁷bromine, ¹²⁹cesium, ⁷³selenium, ⁷²selenium, ⁷²arsenic, ¹⁰³palladium, ²⁰³lead, ¹¹¹indium, ⁵²iron, ¹⁶⁷thulium, ⁵⁷nickel, ⁶²zinc, ⁶¹copper, ²⁰¹thallium, and ¹²³iodine.
[44" id="US-20010009656-A1-CLM-00044] 43. The method according to
claim 39 wherein said composition further comprises a non-radioactive contrast agent.
[45" id="US-20010009656-A1-CLM-00045] 44. The method according to
claim 43 wherein said non-radioactive contrast agent is water soluble.
[46" id="US-20010009656-A1-CLM-00046] 45. The method according to
claim 44 wherein said water soluble non-radioactive contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
[47" id="US-20010009656-A1-CLM-00047] 46. The method according to
claim 43 wherein said non-radioactive contrast agent is water insoluble.
[48" id="US-20010009656-A1-CLM-00048] 47. The method according to
claim 46 wherein said water insoluble contrast agent is tantalum, tantalum oxide, barium sulfate, tungsten, gold and platinum.
[49" id="US-20010009656-A1-CLM-00049] 48. A method for causing necrosis to a portion of a solid mass tumor which method comprises:
(a) identifying a solid mass tumor in a mammal;
(b) injecting a sufficient amount of an embolic composition comprising a biocompatible polymer, a biocompatible solvent and a water insoluble radioisotope into said tumor under conditions wherein a precipitate is formed wherein the radioisotope is employed in an amount effective to cause necrosis of at least a portion of said tumor

类似技术:

---

公开号 | 公开日 | 专利标题

---

US6562317B2|2003-05-13|Radioactive embolizing compositions

---

US6759028B2|2004-07-06|Methods for treating AVM&#39;s using radioactive compositions

---

JP2001521911A5|2009-05-28|

---

US6241719B1|2001-06-05|Method for forming a radioactive stent

---

US5942209A|1999-08-24|Method of local radiotherapy by polymerizing a material in vivo to form a hydrogel

---

JP5079510B2|2012-11-21|Microspheres capable of binding radioisotopes and optionally containing metal microparticles, and methods for their use

---

US8697030B2|2014-04-15|Particulate materials for radiotherapy and diagnostics

---

US7374568B2|2008-05-20|Methods for embolizing aneurysmal sites with a high viscosity embolizing composition

同族专利:

---

公开号 | 公开日

---

EP1028757A1|2000-08-23|

---

JP2001521911A|2001-11-13|

---

DE69828436D1|2005-02-03|

---

WO1999022774A1|1999-05-14|

---

WO1999022775A1|1999-05-14|

---

US6562317B2|2003-05-13|

---

EP1028758B1|2005-05-04|

---

ES2234166T3|2005-06-16|

---

CA2307190A1|1999-05-14|

---

US6015541A|2000-01-18|

---

US6214315B1|2001-04-10|

---

AT294595T|2005-05-15|

---

AU1270599A|1999-05-24|

---

DE69828436T2|2006-01-05|

---

US6168777B1|2001-01-02|

---

EP1028758A1|2000-08-23|

---

EP1028757B1|2004-12-29|

---

AU1378499A|1999-05-24|

---

AT285798T|2005-01-15|

---

EP1028758A4|2002-11-27|

---

JP4416942B2|2010-02-17|

---

CA2307191A1|1999-05-14|

---

DE69830072D1|2005-06-09|

---

EP1028757A4|2002-11-27|

---

JP2001521912A|2001-11-13|

---

USRE39456E1|2007-01-02|

---

DE69830072T2|2006-01-19|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US7645474B1|2003-07-31|2010-01-12|Advanced Cardiovascular Systems, Inc.|Method and system of purifying polymers for use with implantable medical devices|

---

US7785512B1|2003-07-31|2010-08-31|Advanced Cardiovascular Systems, Inc.|Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices|US3527224A|1967-09-05|1970-09-08|American Cyanamid Co|Method of surgically bonding tissue together|

---

US3591676A|1968-11-01|1971-07-06|Eastman Kodak Co|Surgical adhesive compositions|

---

US4268495A|1979-01-08|1981-05-19|Ethicon, Inc.|Injectable embolization and occlusion solution|

---

US4795741A|1987-05-06|1989-01-03|Biomatrix, Inc.|Compositions for therapeutic percutaneous embolization and the use thereof|

---

US4938763B1|1988-10-03|1995-07-04|Atrix Lab Inc|Biodegradable in-situ forming implants and method of producing the same|

---

US5514379A|1992-08-07|1996-05-07|The General Hospital Corporation|Hydrogel compositions and methods of use|

---

US5443454A|1992-12-09|1995-08-22|Terumo Kabushiki Kaisha|Catheter for embolectomy|

---

FI92734C|1993-02-11|1994-12-27|Valmet Paper Machinery Inc|Method of coating a roll in a paper machine and a coated roll in a paper machine|

---

US5383899A|1993-09-28|1995-01-24|Hammerslag; Julius G.|Method of using a surface opening adhesive sealer|

---

US5762903A|1995-03-10|1998-06-09|Korea Atomic Energy Research Institute|Radioactive chitosan complex for radiation therapy|

---

US5667767A|1995-07-27|1997-09-16|Micro Therapeutics, Inc.|Compositions for use in embolizing blood vessels|

---

US5580568A|1995-07-27|1996-12-03|Micro Therapeutics, Inc.|Cellulose diacetate compositions for use in embolizing blood vessels|

---

US5651896A|1995-08-15|1997-07-29|Wheelabrator Clean Air Systems Inc.|Sulfur separation system with interface control|

---

US5888546A|1995-08-28|1999-03-30|The Regents Of The University Of California|Embolic material for endovascular occlusion of abnormal vasculature and method for using the same|

---

JP2000509014A|1996-03-11|2000-07-18|フォーカル，インコーポレイテッド|Polymer delivery of radionuclides and radiopharmaceuticals|

---

WO1997045131A1|1996-05-31|1997-12-04|Micro Therapeutics, Inc.|Compositions for use in embolizing blood vessels|

---

US5695480A|1996-07-29|1997-12-09|Micro Therapeutics, Inc.|Embolizing compositions|

---

DE69729569T2|1996-07-29|2005-06-23|Micro Therapeutics, Inc., San Clemente|KIT OF THREE GLASS VASES FOR VASCULAR EMBOLIZATION USING A MEDIUM CONTAINING DIMETHYL SUULFOXYD|

---

US5966490A|1997-03-21|1999-10-12|Sdl, Inc.|Clad optic fiber, and process for production thereof|

---

EP0927558A1|1997-12-31|1999-07-07|Nycomed Imaging As|Embolizing compositions comprising surfactants|

---

US6059766A|1998-02-27|2000-05-09|Micro Therapeutics, Inc.|Gynecologic embolotherapy methods|US20050255039A1|1998-06-26|2005-11-17|Pro Surg, Inc., A California Corporation|Gel injection treatment of breast, fibroids & endometrial ablation|

---

US7682647B2|1999-09-03|2010-03-23|Advanced Cardiovascular Systems, Inc.|Thermal treatment of a drug eluting implantable medical device|

---

US20020058882A1|1998-06-22|2002-05-16|Artemis Medical, Incorporated|Biopsy localization method and device|

---

US8172897B2|1997-04-15|2012-05-08|Advanced Cardiovascular Systems, Inc.|Polymer and metal composite implantable medical devices|

---

US6240616B1|1997-04-15|2001-06-05|Advanced Cardiovascular Systems, Inc.|Method of manufacturing a medicated porous metal prosthesis|

---

US10028851B2|1997-04-15|2018-07-24|Advanced Cardiovascular Systems, Inc.|Coatings for controlling erosion of a substrate of an implantable medical device|

---

US6776792B1|1997-04-24|2004-08-17|Advanced Cardiovascular Systems Inc.|Coated endovascular stent|

---

CA2291622C|1997-06-06|2007-09-04|Anna Gutowska|Reversible geling co-polymer and method of making|

---

US7637948B2|1997-10-10|2009-12-29|Senorx, Inc.|Tissue marking implant|

---

US8668737B2|1997-10-10|2014-03-11|Senorx, Inc.|Tissue marking implant|

---

US8288745B2|1997-10-10|2012-10-16|Senorx, Inc.|Method of utilizing an implant for targeting external beam radiation|

---

US6375634B1|1997-11-19|2002-04-23|Oncology Innovations, Inc.|Apparatus and method to encapsulate, kill and remove malignancies, including selectively increasing absorption of x-rays and increasing free-radical damage to residual tumors targeted by ionizing and non-ionizing radiation therapy|

---

US6296831B1|1998-04-10|2001-10-02|Battelle Memorial Institute|Stimulus sensitive gel with radioisotope and methods of making|

---

US20040228794A1|1998-04-10|2004-11-18|Battelle Memorial Institute|Therapeutic agent carrier compositions|

---

US6270464B1|1998-06-22|2001-08-07|Artemis Medical, Inc.|Biopsy localization method and device|

---

US6068999A|1998-06-25|2000-05-30|Hendrix; Curt|Dietary supplement for supporting cerebrovascular tone and treating migraine headaches|

---

US20040047804A1|1998-10-29|2004-03-11|The General Hospital Corporation, A Massachusetts Corporation|Enhanced radiation therapy|

---

US6689043B1|1998-11-06|2004-02-10|Amersham Plc|Products and methods for brachytherapy|

---

US6254601B1|1998-12-08|2001-07-03|Hysterx, Inc.|Methods for occlusion of the uterine arteries|

---

AR022404A1|1999-01-25|2002-09-04|Photogen Inc|METHOD AND AGENTS FOR IMPROVED RADIATION THERAPY|

---

US6347241B2|1999-02-02|2002-02-12|Senorx, Inc.|Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it|

---

US8361082B2|1999-02-02|2013-01-29|Senorx, Inc.|Marker delivery device with releasable plug|

---

US8498693B2|1999-02-02|2013-07-30|Senorx, Inc.|Intracorporeal marker and marker delivery device|

---

US6161034A|1999-02-02|2000-12-12|Senorx, Inc.|Methods and chemical preparations for time-limited marking of biopsy sites|

---

US6725083B1|1999-02-02|2004-04-20|Senorx, Inc.|Tissue site markers for in VIVO imaging|

---

US9820824B2|1999-02-02|2017-11-21|Senorx, Inc.|Deployment of polysaccharide markers for treating a site within a patent|

---

EP1919388B1|2000-11-20|2012-12-26|Senorx, Inc.|Tissue site markers for in vivo imaging|

---

US6862470B2|1999-02-02|2005-03-01|Senorx, Inc.|Cavity-filling biopsy site markers|

---

KR100423859B1|1999-05-03|2004-03-22|이 규 호|Vascular Embolic Materials Having Complex Functions|

---

US6333020B1|1999-05-13|2001-12-25|Micro Therapeutics, Inc.|Methods for treating AVM's using radio active compositions|

---

CA2371321C|1999-05-21|2008-12-23|Microtherapeutics, Inc.|Novel high viscosity embolizing compositions|

---

US6575991B1|1999-06-17|2003-06-10|Inrad, Inc.|Apparatus for the percutaneous marking of a lesion|

---

AU6058000A|1999-07-12|2001-01-30|Scimed Life Systems, Inc.|Liquid based vaso-occlusive compositions|

---

US6759054B2|1999-09-03|2004-07-06|Advanced Cardiovascular Systems, Inc.|Ethylene vinyl alcohol composition and coating|

---

US20040029952A1|1999-09-03|2004-02-12|Yung-Ming Chen|Ethylene vinyl alcohol composition and coating|

---

US6790228B2|1999-12-23|2004-09-14|Advanced Cardiovascular Systems, Inc.|Coating for implantable devices and a method of forming the same|

---

US6713119B2|1999-09-03|2004-03-30|Advanced Cardiovascular Systems, Inc.|Biocompatible coating for a prosthesis and a method of forming the same|

---

US7807211B2|1999-09-03|2010-10-05|Advanced Cardiovascular Systems, Inc.|Thermal treatment of an implantable medical device|

---

US6818247B1|2000-03-31|2004-11-16|Advanced Cardiovascular Systems, Inc.|Ethylene vinyl alcohol-dimethyl acetamide composition and a method of coating a stent|

---

US6908624B2|1999-12-23|2005-06-21|Advanced Cardiovascular Systems, Inc.|Coating for implantable devices and a method of forming the same|

---

US20050238686A1|1999-12-23|2005-10-27|Advanced Cardiovascular Systems, Inc.|Coating for implantable devices and a method of forming the same|

---

US6616591B1|1999-12-08|2003-09-09|Scimed Life Systems, Inc.|Radioactive compositions and methods of use thereof|

---

US6613432B2|1999-12-22|2003-09-02|Biosurface Engineering Technologies, Inc.|Plasma-deposited coatings, devices and methods|

---

US8435550B2|2002-12-16|2013-05-07|Abbot Cardiovascular Systems Inc.|Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device|

---

US20010007083A1|1999-12-29|2001-07-05|Roorda Wouter E.|Device and active component for inhibiting formation of thrombus-inflammatory cell matrix|

---

US6575888B2|2000-01-25|2003-06-10|Biosurface Engineering Technologies, Inc.|Bioabsorbable brachytherapy device|

---

US6626928B1|2000-02-23|2003-09-30|Angiogene, Inc.|Occlusion device for treating aneurysm and use therefor|

---

DE01918975T1|2000-03-24|2006-04-13|Biosphere Medical, Inc., Rockland|Microspheres for active embolization|

---

US20030212022A1|2001-03-23|2003-11-13|Jean-Marie Vogel|Compositions and methods for gene therapy|

---

US6749626B1|2000-03-31|2004-06-15|Advanced Cardiovascular Systems, Inc.|Actinomycin D for the treatment of vascular disease|

---

US7504125B1|2001-04-27|2009-03-17|Advanced Cardiovascular Systems, Inc.|System and method for coating implantable devices|

---

US6503954B1|2000-03-31|2003-01-07|Advanced Cardiovascular Systems, Inc.|Biocompatible carrier containing actinomycin D and a method of forming the same|

---

US8109994B2|2003-01-10|2012-02-07|Abbott Cardiovascular Systems, Inc.|Biodegradable drug delivery material for stent|

---

US7875283B2|2000-04-13|2011-01-25|Advanced Cardiovascular Systems, Inc.|Biodegradable polymers for use with implantable medical devices|

---

US6527801B1|2000-04-13|2003-03-04|Advanced Cardiovascular Systems, Inc.|Biodegradable drug delivery material for stent|

---

US7223279B2|2000-04-21|2007-05-29|Vascular Control Systems, Inc.|Methods for minimally-invasive, non-permanent occlusion of a uterine artery|

---

US20030120306A1|2000-04-21|2003-06-26|Vascular Control System|Method and apparatus for the detection and occlusion of blood vessels|

---

US6550482B1|2000-04-21|2003-04-22|Vascular Control Systems, Inc.|Methods for non-permanent occlusion of a uterine artery|

---

US7682648B1|2000-05-31|2010-03-23|Advanced Cardiovascular Systems, Inc.|Methods for forming polymeric coatings on stents|

---

US6451373B1|2000-08-04|2002-09-17|Advanced Cardiovascular Systems, Inc.|Method of forming a therapeutic coating onto a surface of an implantable prosthesis|

---

DE60141145D1|2000-08-24|2010-03-11|Sidney Lerner||

---

AU9260901A|2000-09-11|2002-03-26|Closure Medical Corp|Bronchial occlusion method and apparatus|

---

US6953560B1|2000-09-28|2005-10-11|Advanced Cardiovascular Systems, Inc.|Barriers for polymer-coated implantable medical devices and methods for making the same|

---

US6716444B1|2000-09-28|2004-04-06|Advanced Cardiovascular Systems, Inc.|Barriers for polymer-coated implantable medical devices and methods for making the same|

---

US6783793B1|2000-10-26|2004-08-31|Advanced Cardiovascular Systems, Inc.|Selective coating of medical devices|

---

US6833153B1|2000-10-31|2004-12-21|Advanced Cardiovascular Systems, Inc.|Hemocompatible coatings on hydrophobic porous polymers|

---

US7807210B1|2000-10-31|2010-10-05|Advanced Cardiovascular Systems, Inc.|Hemocompatible polymers on hydrophobic porous polymers|

---

US6635065B2|2000-11-16|2003-10-21|Vascular Control Systems, Inc.|Doppler directed suture ligation device and method|

---

US6638286B1|2000-11-16|2003-10-28|Vascular Control Systems, Inc.|Doppler directed suture ligation device and method|

---

US6824559B2|2000-12-22|2004-11-30|Advanced Cardiovascular Systems, Inc.|Ethylene-carboxyl copolymers as drug delivery matrices|

---

US6663662B2|2000-12-28|2003-12-16|Advanced Cardiovascular Systems, Inc.|Diffusion barrier layer for implantable devices|

---

US6540776B2|2000-12-28|2003-04-01|Advanced Cardiovascular Systems, Inc.|Sheath for a prosthesis and methods of forming the same|

---

US6503556B2|2000-12-28|2003-01-07|Advanced Cardiovascular Systems, Inc.|Methods of forming a coating for a prosthesis|

---

US6527693B2|2001-01-30|2003-03-04|Implant Sciences Corporation|Methods and implants for providing radiation to a patient|

---

US7354444B2|2001-03-28|2008-04-08|Vascular Control Systems, Inc.|Occlusion device with deployable paddles for detection and occlusion of blood vessels|

---

US20030120286A1|2001-03-28|2003-06-26|Vascular Control System|Luminal clip applicator with sensor|

---

CA2442362C|2001-03-28|2009-08-11|Vascular Control Systems, Inc.|Method and apparatus for the detection and ligation of uterine arteries|

---

US20040116522A1|2001-03-30|2004-06-17|Yutaka Yamagata|Medicinal solutions|

---

US6780424B2|2001-03-30|2004-08-24|Charles David Claude|Controlled morphologies in polymer drug for release of drugs from polymer films|

---

US6764505B1|2001-04-12|2004-07-20|Advanced Cardiovascular Systems, Inc.|Variable surface area stent|

---

US6712845B2|2001-04-24|2004-03-30|Advanced Cardiovascular Systems, Inc.|Coating for a stent and a method of forming the same|

---

US6712782B2|2001-05-09|2004-03-30|Varian Medical Systems Technologies, Inc.|Brachytherapy apparatus and methods|

---

US6656506B1|2001-05-09|2003-12-02|Advanced Cardiovascular Systems, Inc.|Microparticle coated medical device|

---

US20030166197A1|2001-05-10|2003-09-04|Ecker Joseph R.|Ethylene insensitive plants|

---

US7651695B2|2001-05-18|2010-01-26|Advanced Cardiovascular Systems, Inc.|Medicated stents for the treatment of vascular disease|

---

US6743462B1|2001-05-31|2004-06-01|Advanced Cardiovascular Systems, Inc.|Apparatus and method for coating implantable devices|

---

US7862495B2|2001-05-31|2011-01-04|Advanced Cardiovascular Systems, Inc.|Radiation or drug delivery source with activity gradient to minimize edge effects|

---

US7622146B2|2002-07-18|2009-11-24|Advanced Cardiovascular Systems, Inc.|Rate limiting barriers for implantable devices and methods for fabrication thereof|

---

US7247313B2|2001-06-27|2007-07-24|Advanced Cardiovascular Systems, Inc.|Polyacrylates coatings for implantable medical devices|

---

US8741378B1|2001-06-27|2014-06-03|Advanced Cardiovascular Systems, Inc.|Methods of coating an implantable device|

---

US6695920B1|2001-06-27|2004-02-24|Advanced Cardiovascular Systems, Inc.|Mandrel for supporting a stent and a method of using the mandrel to coat a stent|

---

US7175873B1|2001-06-27|2007-02-13|Advanced Cardiovascular Systems, Inc.|Rate limiting barriers for implantable devices and methods for fabrication thereof|

---

US6565659B1|2001-06-28|2003-05-20|Advanced Cardiovascular Systems, Inc.|Stent mounting assembly and a method of using the same to coat a stent|

---

US6656216B1|2001-06-29|2003-12-02|Advanced Cardiovascular Systems, Inc.|Composite stent with regioselective material|

---

US7246321B2|2001-07-13|2007-07-17|Anoto Ab|Editing data|

---

US7682669B1|2001-07-30|2010-03-23|Advanced Cardiovascular Systems, Inc.|Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device|

---

US7687053B2|2001-08-20|2010-03-30|Boston Scientific Scimed, Inc.|Embolic compositions with non-cyanoacrylate rheology modifying agents|

---

US7266725B2|2001-09-03|2007-09-04|Pact Xpp Technologies Ag|Method for debugging reconfigurable architectures|

---

US8303651B1|2001-09-07|2012-11-06|Advanced Cardiovascular Systems, Inc.|Polymeric coating for reducing the rate of release of a therapeutic substance from a stent|

---

US7989018B2|2001-09-17|2011-08-02|Advanced Cardiovascular Systems, Inc.|Fluid treatment of a polymeric coating on an implantable medical device|

---

US6863683B2|2001-09-19|2005-03-08|Abbott Laboratoris Vascular Entities Limited|Cold-molding process for loading a stent onto a stent delivery system|

---

US6753071B1|2001-09-27|2004-06-22|Advanced Cardiovascular Systems, Inc.|Rate-reducing membrane for release of an agent|

---

US7223282B1|2001-09-27|2007-05-29|Advanced Cardiovascular Systems, Inc.|Remote activation of an implantable device|

---

US7585516B2|2001-11-12|2009-09-08|Advanced Cardiovascular Systems, Inc.|Coatings for drug delivery devices|

---

US7175874B1|2001-11-30|2007-02-13|Advanced Cardiovascular Systems, Inc.|Apparatus and method for coating implantable devices|

---

US6663880B1|2001-11-30|2003-12-16|Advanced Cardiovascular Systems, Inc.|Permeabilizing reagents to increase drug delivery and a method of local delivery|

---

US6709514B1|2001-12-28|2004-03-23|Advanced Cardiovascular Systems, Inc.|Rotary coating apparatus for coating implantable medical devices|

---

US7919075B1|2002-03-20|2011-04-05|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices|

---

US7022334B1|2002-03-20|2006-04-04|Advanced Cardiovascular Systems, Inc.|Therapeutic composition and a method of coating implantable medical devices|

---

US20070032853A1|2002-03-27|2007-02-08|Hossainy Syed F|40-O-ethyl-rapamycin coated stent|

---

US7207996B2|2002-04-04|2007-04-24|Vascular Control Systems, Inc.|Doppler directed suturing and compression device and method|

---

US20030199917A1|2002-04-22|2003-10-23|Knudson Mark B.|Thrombus treatment with emboli management|

---

FR2839450B1|2002-05-07|2006-04-07|Aboville Marc D|MEDICAMENT PREPARATION IN PARTICULAR FOR THE TREATMENT OF HERNIES DISCALES|

---

US7459142B2|2002-06-06|2008-12-02|Micro Therapeutics, Inc.|High viscosity embolizing compositions comprising prepolymers|

---

US7651505B2|2002-06-17|2010-01-26|Senorx, Inc.|Plugged tip delivery for marker placement|

---

US7033602B1|2002-06-21|2006-04-25|Advanced Cardiovascular Systems, Inc.|Polycationic peptide coatings and methods of coating implantable medical devices|

---

US7794743B2|2002-06-21|2010-09-14|Advanced Cardiovascular Systems, Inc.|Polycationic peptide coatings and methods of making the same|

---

US8506617B1|2002-06-21|2013-08-13|Advanced Cardiovascular Systems, Inc.|Micronized peptide coated stent|

---

US7217426B1|2002-06-21|2007-05-15|Advanced Cardiovascular Systems, Inc.|Coatings containing polycationic peptides for cardiovascular therapy|

---

US7056523B1|2002-06-21|2006-06-06|Advanced Cardiovascular Systems, Inc.|Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine|

---

US7396539B1|2002-06-21|2008-07-08|Advanced Cardiovascular Systems, Inc.|Stent coatings with engineered drug release rate|

---

US7294329B1|2002-07-18|2007-11-13|Advanced Cardiovascular Systems, Inc.|Poly coatings for implantable medical devices|

---

US7363074B1|2002-08-20|2008-04-22|Advanced Cardiovascular Systems, Inc.|Coatings comprising self-assembled molecular structures and a method of delivering a drug using the same|

---

US20040054104A1|2002-09-05|2004-03-18|Pacetti Stephen D.|Coatings for drug delivery devices comprising modified poly|

---

US7732535B2|2002-09-05|2010-06-08|Advanced Cardiovascular Systems, Inc.|Coating for controlled release of drugs from implantable medical devices|

---

US7201935B1|2002-09-17|2007-04-10|Advanced Cardiovascular Systems, Inc.|Plasma-generated coatings for medical devices and methods for fabricating thereof|

---

US20040063805A1|2002-09-19|2004-04-01|Pacetti Stephen D.|Coatings for implantable medical devices and methods for fabrication thereof|

---

US7438722B1|2002-09-20|2008-10-21|Advanced Cardiovascular Systems, Inc.|Method for treatment of restenosis|

---

US7232573B1|2002-09-26|2007-06-19|Advanced Cardiovascular Systems, Inc.|Stent coatings containing self-assembled monolayers|

---

US8202530B2|2002-09-27|2012-06-19|Advanced Cardiovascular Systems, Inc.|Biocompatible coatings for stents|

---

US20070053994A1|2003-03-27|2007-03-08|Egil Jellum|Anti-inflammatory treatment|

---

US8337937B2|2002-09-30|2012-12-25|Abbott Cardiovascular Systems Inc.|Stent spin coating method|

---

US7404979B1|2002-09-30|2008-07-29|Advanced Cardiovascular Systems Inc.|Spin coating apparatus and a method for coating implantable devices|

---

US7087263B2|2002-10-09|2006-08-08|Advanced Cardiovascular Systems, Inc.|Rare limiting barriers for implantable medical devices|

---

US20060069168A1|2002-10-29|2006-03-30|Norikazu Tabata|Vascular embolization material|

---

US20060271168A1|2002-10-30|2006-11-30|Klaus Kleine|Degradable medical device|

---

EP1578455A4|2002-11-04|2008-12-31|Biosphere Medical Inc|Radioisotope-associated polymeric hydrogel microspheres and methods for producing and using the same|

---

US7169178B1|2002-11-12|2007-01-30|Advanced Cardiovascular Systems, Inc.|Stent with drug coating|

---

US8034361B2|2002-11-12|2011-10-11|Advanced Cardiovascular Systems, Inc.|Stent coatings incorporating nanoparticles|

---

US6896965B1|2002-11-12|2005-05-24|Advanced Cardiovascular Systems, Inc.|Rate limiting barriers for implantable devices|

---

US7022372B1|2002-11-12|2006-04-04|Advanced Cardiovascular Systems, Inc.|Compositions for coating implantable medical devices|

---

US20060036158A1|2003-11-17|2006-02-16|Inrad, Inc.|Self-contained, self-piercing, side-expelling marking apparatus|

---

US20040097961A1|2002-11-19|2004-05-20|Vascular Control System|Tenaculum for use with occlusion devices|

---

US7172603B2|2002-11-19|2007-02-06|Vascular Control Systems, Inc.|Deployable constrictor for uterine artery occlusion|

---

US6982004B1|2002-11-26|2006-01-03|Advanced Cardiovascular Systems, Inc.|Electrostatic loading of drugs on implantable medical devices|

---

US7211150B1|2002-12-09|2007-05-01|Advanced Cardiovascular Systems, Inc.|Apparatus and method for coating and drying multiple stents|

---

US7776926B1|2002-12-11|2010-08-17|Advanced Cardiovascular Systems, Inc.|Biocompatible coating for implantable medical devices|

---

US7758880B2|2002-12-11|2010-07-20|Advanced Cardiovascular Systems, Inc.|Biocompatible polyacrylate compositions for medical applications|

---

US7074276B1|2002-12-12|2006-07-11|Advanced Cardiovascular Systems, Inc.|Clamp mandrel fixture and a method of using the same to minimize coating defects|

---

US7404821B2|2003-01-30|2008-07-29|Vascular Control Systems, Inc.|Treatment for post partum hemorrhage|

---

US7651511B2|2003-02-05|2010-01-26|Vascular Control Systems, Inc.|Vascular clamp for caesarian section|

---

US7255891B1|2003-02-26|2007-08-14|Advanced Cardiovascular Systems, Inc.|Method for coating implantable medical devices|

---

US6926919B1|2003-02-26|2005-08-09|Advanced Cardiovascular Systems, Inc.|Method for fabricating a coating for a medical device|

---

US7063884B2|2003-02-26|2006-06-20|Advanced Cardiovascular Systems, Inc.|Stent coating|

---

US8715771B2|2003-02-26|2014-05-06|Abbott Cardiovascular Systems Inc.|Coated stent and method of making the same|

---

US7563483B2|2003-02-26|2009-07-21|Advanced Cardiovascular Systems Inc.|Methods for fabricating a coating for implantable medical devices|

---

US7288609B1|2003-03-04|2007-10-30|Advanced Cardiovascular Systems, Inc.|Coatings for drug delivery devices based on poly |

---

US7333844B2|2003-03-28|2008-02-19|Vascular Control Systems, Inc.|Uterine tissue monitoring device and method|

---

US20040202694A1|2003-04-11|2004-10-14|Vascular Control Systems, Inc.|Embolic occlusion of uterine arteries|

---

US7563454B1|2003-05-01|2009-07-21|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices|

---

US8791171B2|2003-05-01|2014-07-29|Abbott Cardiovascular Systems Inc.|Biodegradable coatings for implantable medical devices|

---

US7279174B2|2003-05-08|2007-10-09|Advanced Cardiovascular Systems, Inc.|Stent coatings comprising hydrophilic additives|

---

US7323209B1|2003-05-15|2008-01-29|Advanced Cardiovascular Systems, Inc.|Apparatus and method for coating stents|

---

US7983734B2|2003-05-23|2011-07-19|Senorx, Inc.|Fibrous marker and intracorporeal delivery thereof|

---

US7877133B2|2003-05-23|2011-01-25|Senorx, Inc.|Marker or filler forming fluid|

---

US20050119562A1|2003-05-23|2005-06-02|Senorx, Inc.|Fibrous marker formed of synthetic polymer strands|

---

US7186789B2|2003-06-11|2007-03-06|Advanced Cardiovascular Systems, Inc.|Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings|

---

US7285304B1|2003-06-25|2007-10-23|Advanced Cardiovascular Systems, Inc.|Fluid treatment of a polymeric coating on an implantable medical device|

---

US7645504B1|2003-06-26|2010-01-12|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers|

---

US7875285B1|2003-07-15|2011-01-25|Advanced Cardiovascular Systems, Inc.|Medicated coatings for implantable medical devices having controlled rate of release|

---

US20050021127A1|2003-07-21|2005-01-27|Kawula Paul John|Porous glass fused onto stent for drug retention|

---

US20050027196A1|2003-07-30|2005-02-03|Fitzgerald Loretta A.|System for processing patient radiation treatment data|

---

US7169404B2|2003-07-30|2007-01-30|Advanced Cardiovasular Systems, Inc.|Biologically absorbable coatings for implantable devices and methods for fabricating the same|

---

US7056591B1|2003-07-30|2006-06-06|Advanced Cardiovascular Systems, Inc.|Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same|

---

US7431959B1|2003-07-31|2008-10-07|Advanced Cardiovascular Systems Inc.|Method and system for irradiation of a drug eluting implantable medical device|

---

AU2004270070B2|2003-09-08|2007-10-18|Dong Wha Pharm., Ind., Co., Ltd|A radioisotope-chitosan complex for treatment of prostate cancer|

---

US7906125B2|2003-09-18|2011-03-15|Boston Scientific Scimed, Inc.|Solid or semi-solid therapeutic formulations|

---

US7226622B2|2003-09-18|2007-06-05|Boston Scientific Scimed, Inc.|Chemoablation of tissue using biodegradable, solid salt dosage forms|

---

US20050064045A1|2003-09-18|2005-03-24|Sheng-Ping Zhong|Injectable therapeutic formulations|

---

AU2004275878B2|2003-09-25|2011-04-14|Rutgers, The State University|Inherently radiopaque polymeric products for embolotherapy|

---

US7441513B1|2003-09-26|2008-10-28|Advanced Cardiovascular Systems, Inc.|Plasma-generated coating apparatus for medical devices and a method of coating deposition|

---

US7318932B2|2003-09-30|2008-01-15|Advanced Cardiovascular Systems, Inc.|Coatings for drug delivery devices comprising hydrolitically stable adducts of poly and methods for fabricating the same|

---

US7198675B2|2003-09-30|2007-04-03|Advanced Cardiovascular Systems|Stent mandrel fixture and method for selectively coating surfaces of a stent|

---

US7704544B2|2003-10-07|2010-04-27|Advanced Cardiovascular Systems, Inc.|System and method for coating a tubular implantable medical device|

---

US20050090804A1|2003-10-22|2005-04-28|Trivascular, Inc.|Endoluminal prosthesis endoleak management|

---

US7329413B1|2003-11-06|2008-02-12|Advanced Cardiovascular Systems, Inc.|Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof|

---

US7261946B2|2003-11-14|2007-08-28|Advanced Cardiovascular Systems, Inc.|Block copolymers of acrylates and methacrylates with fluoroalkenes|

---

US9114198B2|2003-11-19|2015-08-25|Advanced Cardiovascular Systems, Inc.|Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same|

---

US7325546B2|2003-11-20|2008-02-05|Vascular Control Systems, Inc.|Uterine artery occlusion device with cervical receptacle|

---

US8192752B2|2003-11-21|2012-06-05|Advanced Cardiovascular Systems, Inc.|Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same|

---

US7560492B1|2003-11-25|2009-07-14|Advanced Cardiovascular Systems, Inc.|Polysulfone block copolymers as drug-eluting coating material|

---

US7686817B2|2003-11-25|2010-03-30|Vascular Control Systems, Inc.|Occlusion device for asymmetrical uterine artery anatomy|

---

US7807722B2|2003-11-26|2010-10-05|Advanced Cardiovascular Systems, Inc.|Biobeneficial coating compositions and methods of making and using thereof|

---

US20050118344A1|2003-12-01|2005-06-02|Pacetti Stephen D.|Temperature controlled crimping|

---

US7220816B2|2003-12-16|2007-05-22|Advanced Cardiovascular Systems, Inc.|Biologically absorbable coatings for implantable devices based on poly and methods for fabricating the same|

---

US7435788B2|2003-12-19|2008-10-14|Advanced Cardiovascular Systems, Inc.|Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents|

---

US8309112B2|2003-12-24|2012-11-13|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same|

---

US8685431B2|2004-03-16|2014-04-01|Advanced Cardiovascular Systems, Inc.|Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same|

---

US8551512B2|2004-03-22|2013-10-08|Advanced Cardiovascular Systems, Inc.|Polyethylene glycol/poly copolymer coated devices including EVEROLIMUS|

---

US20050208093A1|2004-03-22|2005-09-22|Thierry Glauser|Phosphoryl choline coating compositions|

---

US20050214339A1|2004-03-29|2005-09-29|Yiwen Tang|Biologically degradable compositions for medical applications|

---

US8778014B1|2004-03-31|2014-07-15|Advanced Cardiovascular Systems, Inc.|Coatings for preventing balloon damage to polymer coated stents|

---

US8293890B2|2004-04-30|2012-10-23|Advanced Cardiovascular Systems, Inc.|Hyaluronic acid based copolymers|

---

US20050288481A1|2004-04-30|2005-12-29|Desnoyer Jessica R|Design of poly for the control of agent-release from polymeric compositions|

---

US7820732B2|2004-04-30|2010-10-26|Advanced Cardiovascular Systems, Inc.|Methods for modulating thermal and mechanical properties of coatings on implantable devices|

---

US20050265960A1|2004-05-26|2005-12-01|Pacetti Stephen D|Polymers containing poly and agents for use with medical articles and methods of fabricating the same|

---

US9561309B2|2004-05-27|2017-02-07|Advanced Cardiovascular Systems, Inc.|Antifouling heparin coatings|

---

US20050273002A1|2004-06-04|2005-12-08|Goosen Ryan L|Multi-mode imaging marker|

---

US7563780B1|2004-06-18|2009-07-21|Advanced Cardiovascular Systems, Inc.|Heparin prodrugs and drug delivery stents formed therefrom|

---

US8568469B1|2004-06-28|2013-10-29|Advanced Cardiovascular Systems, Inc.|Stent locking element and a method of securing a stent on a delivery system|

---

US20050287184A1|2004-06-29|2005-12-29|Hossainy Syed F A|Drug-delivery stent formulations for restenosis and vulnerable plaque|

---

US8241554B1|2004-06-29|2012-08-14|Advanced Cardiovascular Systems, Inc.|Method of forming a stent pattern on a tube|

---

US20060002968A1|2004-06-30|2006-01-05|Gordon Stewart|Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders|

---

US7758881B2|2004-06-30|2010-07-20|Advanced Cardiovascular Systems, Inc.|Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device|

---

US20060015144A1|2004-07-19|2006-01-19|Vascular Control Systems, Inc.|Uterine artery occlusion staple|

---

US20060020330A1|2004-07-26|2006-01-26|Bin Huang|Method of fabricating an implantable medical device with biaxially oriented polymers|

---

US8357391B2|2004-07-30|2013-01-22|Advanced Cardiovascular Systems, Inc.|Coatings for implantable devices comprising polyand diacid linkages|

---

US7494665B1|2004-07-30|2009-02-24|Advanced Cardiovascular Systems, Inc.|Polymers containing siloxane monomers|

---

US20060041102A1|2004-08-23|2006-02-23|Advanced Cardiovascular Systems, Inc.|Implantable devices comprising biologically absorbable polymers having constant rate of degradation and methods for fabricating the same|

---

US9283099B2|2004-08-25|2016-03-15|Advanced Cardiovascular Systems, Inc.|Stent-catheter assembly with a releasable connection for stent retention|

---

US7648727B2|2004-08-26|2010-01-19|Advanced Cardiovascular Systems, Inc.|Methods for manufacturing a coated stent-balloon assembly|

---

US7244443B2|2004-08-31|2007-07-17|Advanced Cardiovascular Systems, Inc.|Polymers of fluorinated monomers and hydrophilic monomers|

---

US7229471B2|2004-09-10|2007-06-12|Advanced Cardiovascular Systems, Inc.|Compositions containing fast-leaching plasticizers for improved performance of medical devices|

---

US8110211B2|2004-09-22|2012-02-07|Advanced Cardiovascular Systems, Inc.|Medicated coatings for implantable medical devices including polyacrylates|

---

CA2579612A1|2004-09-24|2006-04-06|Biosphere Medical, Inc.|Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof|

---

US8043553B1|2004-09-30|2011-10-25|Advanced Cardiovascular Systems, Inc.|Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article|

---

US8778256B1|2004-09-30|2014-07-15|Advanced Cardiovascular Systems, Inc.|Deformation of a polymer tube in the fabrication of a medical article|

---

US8173062B1|2004-09-30|2012-05-08|Advanced Cardiovascular Systems, Inc.|Controlled deformation of a polymer tube in fabricating a medical article|

---

US7875233B2|2004-09-30|2011-01-25|Advanced Cardiovascular Systems, Inc.|Method of fabricating a biaxially oriented implantable medical device|

---

US7166680B2|2004-10-06|2007-01-23|Advanced Cardiovascular Systems, Inc.|Blends of poly polymers|

---

US20060089485A1|2004-10-27|2006-04-27|Desnoyer Jessica R|End-capped poly copolymers|

---

US8603634B2|2004-10-27|2013-12-10|Abbott Cardiovascular Systems Inc.|End-capped poly copolymers|

---

US7875036B2|2004-10-27|2011-01-25|Vascular Control Systems, Inc.|Short term treatment for uterine disorder|

---

US20060093639A1|2004-10-29|2006-05-04|Starkebaum Warren L|Method and device for destroying body tissue|

---

US7390497B2|2004-10-29|2008-06-24|Advanced Cardiovascular Systems, Inc.|Poly filler blends for modulation of coating properties|

---

US20060095122A1|2004-10-29|2006-05-04|Advanced Cardiovascular Systems, Inc.|Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same|

---

US7214759B2|2004-11-24|2007-05-08|Advanced Cardiovascular Systems, Inc.|Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same|

---

US8609123B2|2004-11-29|2013-12-17|Advanced Cardiovascular Systems, Inc.|Derivatized poly as a biobeneficial coating|

---

US7588642B1|2004-11-29|2009-09-15|Advanced Cardiovascular Systems, Inc.|Abluminal stent coating apparatus and method using a brush assembly|

---

US20060115449A1|2004-11-30|2006-06-01|Advanced Cardiovascular Systems, Inc.|Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings|

---

US7892592B1|2004-11-30|2011-02-22|Advanced Cardiovascular Systems, Inc.|Coating abluminal surfaces of stents and other implantable medical devices|

---

US7604818B2|2004-12-22|2009-10-20|Advanced Cardiovascular Systems, Inc.|Polymers of fluorinated monomers and hydrocarbon monomers|

---

US7419504B2|2004-12-27|2008-09-02|Advanced Cardiovascular Systems, Inc.|Poly block copolymers|

---

US8007775B2|2004-12-30|2011-08-30|Advanced Cardiovascular Systems, Inc.|Polymers containing poly and agents for use with medical articles and methods of fabricating the same|

---

US7202325B2|2005-01-14|2007-04-10|Advanced Cardiovascular Systems, Inc.|Poly and agents for use with medical articles|

---

CA2594859C|2005-01-14|2013-08-13|Henkel Kommanditgesellschaft Auf Atkien|Radiopaque cyanoacrylate compositions|

---

US20060216431A1|2005-03-28|2006-09-28|Kerrigan Cameron K|Electrostatic abluminal coating of a stent crimped on a balloon catheter|

---

US7520817B2|2005-03-30|2009-04-21|Diamond Billiard Products, Inc.|Billiard cue tips and methods of assembly|

---

US20060224226A1|2005-03-31|2006-10-05|Bin Huang|In-vivo radial orientation of a polymeric implantable medical device|

---

US7381048B2|2005-04-12|2008-06-03|Advanced Cardiovascular Systems, Inc.|Stents with profiles for gripping a balloon catheter and molds for fabricating stents|

---

US10357328B2|2005-04-20|2019-07-23|Bard Peripheral Vascular, Inc. and Bard Shannon Limited|Marking device with retractable cannula|

---

US7795467B1|2005-04-26|2010-09-14|Advanced Cardiovascular Systems, Inc.|Bioabsorbable, biobeneficial polyurethanes for use in medical devices|

---

US8778375B2|2005-04-29|2014-07-15|Advanced Cardiovascular Systems, Inc.|Amorphous poly coating|

---

US8263109B2|2005-05-09|2012-09-11|Boston Scientific Scimed, Inc.|Injectable bulking compositions|

---

BRPI0608766A8|2005-05-09|2018-04-17|Biosphere Medical Sa|substantially spherical microsphere, composition, and methods for drug delivery and active embolization in a mammal|

---

US7862552B2|2005-05-09|2011-01-04|Boston Scientific Scimed, Inc.|Medical devices for treating urological and uterine conditions|

---

US20060251581A1|2005-05-09|2006-11-09|Mcintyre Jon T|Method for treatment of uterine fibroid tumors|

---

US7291166B2|2005-05-18|2007-11-06|Advanced Cardiovascular Systems, Inc.|Polymeric stent patterns|

---

EP1883425A1|2005-05-23|2008-02-06|Universite De Geneve|Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant|

---

US7622070B2|2005-06-20|2009-11-24|Advanced Cardiovascular Systems, Inc.|Method of manufacturing an implantable polymeric medical device|

---

US7823533B2|2005-06-30|2010-11-02|Advanced Cardiovascular Systems, Inc.|Stent fixture and method for reducing coating defects|

---

US8021676B2|2005-07-08|2011-09-20|Advanced Cardiovascular Systems, Inc.|Functionalized chemically inert polymers for coatings|

---

US7785647B2|2005-07-25|2010-08-31|Advanced Cardiovascular Systems, Inc.|Methods of providing antioxidants to a drug containing product|

---

US7735449B1|2005-07-28|2010-06-15|Advanced Cardiovascular Systems, Inc.|Stent fixture having rounded support structures and method for use thereof|

---

US7658880B2|2005-07-29|2010-02-09|Advanced Cardiovascular Systems, Inc.|Polymeric stent polishing method and apparatus|

---

US7297758B2|2005-08-02|2007-11-20|Advanced Cardiovascular Systems, Inc.|Method for extending shelf-life of constructs of semi-crystallizable polymers|

---

US20070038290A1|2005-08-15|2007-02-15|Bin Huang|Fiber reinforced composite stents|

---

US7476245B2|2005-08-16|2009-01-13|Advanced Cardiovascular Systems, Inc.|Polymeric stent patterns|

---

US20070045255A1|2005-08-23|2007-03-01|Klaus Kleine|Laser induced plasma machining with an optimized process gas|

---

US20070045252A1|2005-08-23|2007-03-01|Klaus Kleine|Laser induced plasma machining with a process gas|

---

US9248034B2|2005-08-23|2016-02-02|Advanced Cardiovascular Systems, Inc.|Controlled disintegrating implantable medical devices|

---

US20070049973A1|2005-08-29|2007-03-01|Vascular Control Systems, Inc.|Method and device for treating adenomyosis and endometriosis|

---

CA2562580C|2005-10-07|2014-04-29|Inrad, Inc.|Drug-eluting tissue marker|

---

US20070128246A1|2005-12-06|2007-06-07|Hossainy Syed F A|Solventless method for forming a coating|

---

US20070135909A1|2005-12-08|2007-06-14|Desnoyer Jessica R|Adhesion polymers to improve stent retention|

---

US7976891B1|2005-12-16|2011-07-12|Advanced Cardiovascular Systems, Inc.|Abluminal stent coating apparatus and method of using focused acoustic energy|

---

US7867547B2|2005-12-19|2011-01-11|Advanced Cardiovascular Systems, Inc.|Selectively coating luminal surfaces of stents|

---

US20070151961A1|2006-01-03|2007-07-05|Klaus Kleine|Fabrication of an implantable medical device with a modified laser beam|

---

US20070156230A1|2006-01-04|2007-07-05|Dugan Stephen R|Stents with radiopaque markers|

---

US7951185B1|2006-01-06|2011-05-31|Advanced Cardiovascular Systems, Inc.|Delivery of a stent at an elevated temperature|

---

US20070179219A1|2006-01-31|2007-08-02|Bin Huang|Method of fabricating an implantable medical device using gel extrusion and charge induced orientation|

---

US20070196428A1|2006-02-17|2007-08-23|Thierry Glauser|Nitric oxide generating medical devices|

---

US8349443B2|2006-02-23|2013-01-08|Meadwestvaco Corporation|Method for treating a substrate|

---

US7601383B2|2006-02-28|2009-10-13|Advanced Cardiovascular Systems, Inc.|Coating construct containing poly |

---

US7713637B2|2006-03-03|2010-05-11|Advanced Cardiovascular Systems, Inc.|Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer|

---

US20070231363A1|2006-03-29|2007-10-04|Yung-Ming Chen|Coatings formed from stimulus-sensitive material|

---

US7964210B2|2006-03-31|2011-06-21|Abbott Cardiovascular Systems Inc.|Degradable polymeric implantable medical devices with a continuous phase and discrete phase|

---

US8747878B2|2006-04-28|2014-06-10|Advanced Cardiovascular Systems, Inc.|Method of fabricating an implantable medical device by controlling crystalline structure|

---

US8747879B2|2006-04-28|2014-06-10|Advanced Cardiovascular Systems, Inc.|Method of fabricating an implantable medical device to reduce chance of late inflammatory response|

---

US20070254012A1|2006-04-28|2007-11-01|Ludwig Florian N|Controlled degradation and drug release in stents|

---

US20070259101A1|2006-05-02|2007-11-08|Kleiner Lothar W|Microporous coating on medical devices|

---

US8003156B2|2006-05-04|2011-08-23|Advanced Cardiovascular Systems, Inc.|Rotatable support elements for stents|

---

US7985441B1|2006-05-04|2011-07-26|Yiwen Tang|Purification of polymers for coating applications|

---

US8304012B2|2006-05-04|2012-11-06|Advanced Cardiovascular Systems, Inc.|Method for drying a stent|

---

US7761968B2|2006-05-25|2010-07-27|Advanced Cardiovascular Systems, Inc.|Method of crimping a polymeric stent|

---

US7775178B2|2006-05-26|2010-08-17|Advanced Cardiovascular Systems, Inc.|Stent coating apparatus and method|

---

US8752268B2|2006-05-26|2014-06-17|Abbott Cardiovascular Systems Inc.|Method of making stents with radiopaque markers|

---

US7951194B2|2006-05-26|2011-05-31|Abbott Cardiovascular Sysetms Inc.|Bioabsorbable stent with radiopaque coating|

---

US7959940B2|2006-05-30|2011-06-14|Advanced Cardiovascular Systems, Inc.|Polymer-bioceramic composite implantable medical devices|

---

US7971333B2|2006-05-30|2011-07-05|Advanced Cardiovascular Systems, Inc.|Manufacturing process for polymetric stents|

---

US8343530B2|2006-05-30|2013-01-01|Abbott Cardiovascular Systems Inc.|Polymer-and polymer blend-bioceramic composite implantable medical devices|

---

US8568764B2|2006-05-31|2013-10-29|Advanced Cardiovascular Systems, Inc.|Methods of forming coating layers for medical devices utilizing flash vaporization|

---

US20080058916A1|2006-05-31|2008-03-06|Bin Huang|Method of fabricating polymeric self-expandable stent|

---

US9561351B2|2006-05-31|2017-02-07|Advanced Cardiovascular Systems, Inc.|Drug delivery spiral coil construct|

---

US20070281073A1|2006-06-01|2007-12-06|Gale David C|Enhanced adhesion of drug delivery coatings on stents|

---

US8034287B2|2006-06-01|2011-10-11|Abbott Cardiovascular Systems Inc.|Radiation sterilization of medical devices|

---

US20070282433A1|2006-06-01|2007-12-06|Limon Timothy A|Stent with retention protrusions formed during crimping|

---

US8486135B2|2006-06-01|2013-07-16|Abbott Cardiovascular Systems Inc.|Implantable medical devices fabricated from branched polymers|

---

US8703167B2|2006-06-05|2014-04-22|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug|

---

US20080124372A1|2006-06-06|2008-05-29|Hossainy Syed F A|Morphology profiles for control of agent release rates from polymer matrices|

---

US20070286882A1|2006-06-09|2007-12-13|Yiwen Tang|Solvent systems for coating medical devices|

---

US8778376B2|2006-06-09|2014-07-15|Advanced Cardiovascular Systems, Inc.|Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating|

---

US20070286941A1|2006-06-13|2007-12-13|Bin Huang|Surface treatment of a polymeric stent|

---

US8114150B2|2006-06-14|2012-02-14|Advanced Cardiovascular Systems, Inc.|RGD peptide attached to bioabsorbable stents|

---

US8603530B2|2006-06-14|2013-12-10|Abbott Cardiovascular Systems Inc.|Nanoshell therapy|

---

US8048448B2|2006-06-15|2011-11-01|Abbott Cardiovascular Systems Inc.|Nanoshells for drug delivery|

---

US7731890B2|2006-06-15|2010-06-08|Advanced Cardiovascular Systems, Inc.|Methods of fabricating stents with enhanced fracture toughness|

---

US8535372B1|2006-06-16|2013-09-17|Abbott Cardiovascular Systems Inc.|Bioabsorbable stent with prohealing layer|

---

US8333000B2|2006-06-19|2012-12-18|Advanced Cardiovascular Systems, Inc.|Methods for improving stent retention on a balloon catheter|

---

US20070290412A1|2006-06-19|2007-12-20|John Capek|Fabricating a stent with selected properties in the radial and axial directions|

---

US8017237B2|2006-06-23|2011-09-13|Abbott Cardiovascular Systems, Inc.|Nanoshells on polymers|

---

US9072820B2|2006-06-26|2015-07-07|Advanced Cardiovascular Systems, Inc.|Polymer composite stent with polymer particles|

---

US8128688B2|2006-06-27|2012-03-06|Abbott Cardiovascular Systems Inc.|Carbon coating on an implantable device|

---

US20070299511A1|2006-06-27|2007-12-27|Gale David C|Thin stent coating|

---

US7794776B1|2006-06-29|2010-09-14|Abbott Cardiovascular Systems Inc.|Modification of polymer stents with radiation|

---

US7740791B2|2006-06-30|2010-06-22|Advanced Cardiovascular Systems, Inc.|Method of fabricating a stent with features by blow molding|

---

US20080009938A1|2006-07-07|2008-01-10|Bin Huang|Stent with a radiopaque marker and method for making the same|

---

US9028859B2|2006-07-07|2015-05-12|Advanced Cardiovascular Systems, Inc.|Phase-separated block copolymer coatings for implantable medical devices|

---

US7823263B2|2006-07-11|2010-11-02|Abbott Cardiovascular Systems Inc.|Method of removing stent islands from a stent|

---

US7757543B2|2006-07-13|2010-07-20|Advanced Cardiovascular Systems, Inc.|Radio frequency identification monitoring of stents|

---

US20080014244A1|2006-07-13|2008-01-17|Gale David C|Implantable medical devices and coatings therefor comprising physically crosslinked block copolymers|

---

US7998404B2|2006-07-13|2011-08-16|Advanced Cardiovascular Systems, Inc.|Reduced temperature sterilization of stents|

---

US8685430B1|2006-07-14|2014-04-01|Abbott Cardiovascular Systems Inc.|Tailored aliphatic polyesters for stent coatings|

---

US7794495B2|2006-07-17|2010-09-14|Advanced Cardiovascular Systems, Inc.|Controlled degradation of stents|

---

US7886419B2|2006-07-18|2011-02-15|Advanced Cardiovascular Systems, Inc.|Stent crimping apparatus and method|

---

US8016879B2|2006-08-01|2011-09-13|Abbott Cardiovascular Systems Inc.|Drug delivery after biodegradation of the stent scaffolding|

---

US20090216118A1|2007-07-26|2009-08-27|Senorx, Inc.|Polysaccharide markers|

---

US20080039819A1|2006-08-04|2008-02-14|Senorx, Inc.|Marker formed of starch or other suitable polysaccharide|

---

US8703169B1|2006-08-15|2014-04-22|Abbott Cardiovascular Systems Inc.|Implantable device having a coating comprising carrageenan and a biostable polymer|

---

US9173733B1|2006-08-21|2015-11-03|Abbott Cardiovascular Systems Inc.|Tracheobronchial implantable medical device and methods of use|

---

US7923022B2|2006-09-13|2011-04-12|Advanced Cardiovascular Systems, Inc.|Degradable polymeric implantable medical devices with continuous phase and discrete phase|

---

US7842737B2|2006-09-29|2010-11-30|Abbott Cardiovascular Systems Inc.|Polymer blend-bioceramic composite implantable medical devices|

---

US20080091262A1|2006-10-17|2008-04-17|Gale David C|Drug delivery after biodegradation of the stent scaffolding|

---

ES2443526T3|2006-10-23|2014-02-19|C.R. Bard, Inc.|Breast marker|

---

EP2109409B1|2006-12-12|2018-09-05|C.R.Bard, Inc.|Multiple imaging mode tissue marker|

---

US8597673B2|2006-12-13|2013-12-03|Advanced Cardiovascular Systems, Inc.|Coating of fast absorption or dissolution|

---

US8099849B2|2006-12-13|2012-01-24|Abbott Cardiovascular Systems Inc.|Optimizing fracture toughness of polymeric stent|

---

ES2432572T3|2006-12-18|2013-12-04|C.R. Bard, Inc.|Biopsy marker with imaging properties generated in situ|

---

US20080243228A1|2007-03-28|2008-10-02|Yunbing Wang|Implantable medical devices fabricated from block copolymers|

---

US8262723B2|2007-04-09|2012-09-11|Abbott Cardiovascular Systems Inc.|Implantable medical devices fabricated from polymer blends with star-block copolymers|

---

US8147769B1|2007-05-16|2012-04-03|Abbott Cardiovascular Systems Inc.|Stent and delivery system with reduced chemical degradation|

---

US9056155B1|2007-05-29|2015-06-16|Abbott Cardiovascular Systems Inc.|Coatings having an elastic primer layer|

---

US7829008B2|2007-05-30|2010-11-09|Abbott Cardiovascular Systems Inc.|Fabricating a stent from a blow molded tube|

---

US7959857B2|2007-06-01|2011-06-14|Abbott Cardiovascular Systems Inc.|Radiation sterilization of medical devices|

---

US8202528B2|2007-06-05|2012-06-19|Abbott Cardiovascular Systems Inc.|Implantable medical devices with elastomeric block copolymer coatings|

---

US20080306582A1|2007-06-05|2008-12-11|Yunbing Wang|Implantable medical devices with elastomeric copolymer coatings|

---

US8293260B2|2007-06-05|2012-10-23|Abbott Cardiovascular Systems Inc.|Elastomeric copolymer coatings containing polyfor implantable medical devices|

---

US8425591B1|2007-06-11|2013-04-23|Abbott Cardiovascular Systems Inc.|Methods of forming polymer-bioceramic composite medical devices with bioceramic particles|

---

US8109904B1|2007-06-25|2012-02-07|Abbott Cardiovascular Systems Inc.|Drug delivery medical devices|

---

US8048441B2|2007-06-25|2011-11-01|Abbott Cardiovascular Systems, Inc.|Nanobead releasing medical devices|

---

US7901452B2|2007-06-27|2011-03-08|Abbott Cardiovascular Systems Inc.|Method to fabricate a stent having selected morphology to reduce restenosis|

---

US7955381B1|2007-06-29|2011-06-07|Advanced Cardiovascular Systems, Inc.|Polymer-bioceramic composite implantable medical device with different types of bioceramic particles|

---

US20090041845A1|2007-08-08|2009-02-12|Lothar Walter Kleiner|Implantable medical devices having thin absorbable coatings|

---

EP2219692A2|2007-11-13|2010-08-25|Boston Scientific Scimed, Inc.|Combination coil and liquid embolic for embolization|

---

US8211489B2|2007-12-19|2012-07-03|Abbott Cardiovascular Systems, Inc.|Methods for applying an application material to an implantable device|

---

US8361538B2|2007-12-19|2013-01-29|Abbott Laboratories|Methods for applying an application material to an implantable device|

---

US8311610B2|2008-01-31|2012-11-13|C. R. Bard, Inc.|Biopsy tissue marker|

---

KR101643371B1|2008-08-19|2016-07-27|마이크로 테라퓨틱스 인코포레이티드|Detachable tip microcatheter|

---

US9327061B2|2008-09-23|2016-05-03|Senorx, Inc.|Porous bioabsorbable implant|

---

EP3005971A3|2008-12-30|2016-07-20|C.R. Bard, Inc.|Marker delivery device for tissue marker placement|

---

US8808353B2|2010-01-30|2014-08-19|Abbott Cardiovascular Systems Inc.|Crush recoverable polymer scaffolds having a low crossing profile|

---

US8568471B2|2010-01-30|2013-10-29|Abbott Cardiovascular Systems Inc.|Crush recoverable polymer scaffolds|

---

EP2353624A1|2010-02-10|2011-08-10|Université de la Méditerranée - Aix-Marseille II|Embolic material, its process of preparation and its therapeutical uses thereof|

---

US8685433B2|2010-03-31|2014-04-01|Abbott Cardiovascular Systems Inc.|Absorbable coating for implantable device|

---

WO2013130877A1|2012-02-29|2013-09-06|206 Ortho, Inc.|Method and apparatus for treating bone fractures, including the use of composite implants|

---

WO2015095745A1|2010-10-20|2015-06-25|206 Ortho, Inc.|Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications|

---

WO2012054742A2|2010-10-20|2012-04-26|BIOS2 Medical, Inc.|Implantable polymer for bone and vascular lesions|

---

US11058796B2|2010-10-20|2021-07-13|206 Ortho, Inc.|Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications|

---

US10525169B2|2010-10-20|2020-01-07|206 Ortho, Inc.|Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications|

---

US11207109B2|2010-10-20|2021-12-28|206 Ortho, Inc.|Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications|

---

GB2490317A|2011-04-19|2012-10-31|Dspi Ltd|Radioactive solution undergoing in situ precipitation at a tumour site for cancer therapy|

---

US8726483B2|2011-07-29|2014-05-20|Abbott Cardiovascular Systems Inc.|Methods for uniform crimping and deployment of a polymer scaffold|

---

US20130046375A1|2011-08-17|2013-02-21|Meng Chen|Plasma modified medical devices and methods|

---

BR112014031223A2|2012-06-14|2017-06-27|Microvention Inc|polymer treatment compositions|

---

US10124087B2|2012-06-19|2018-11-13|Covidien Lp|Detachable coupling for catheter|

---

CA2887604C|2012-10-15|2021-05-18|Microvention, Inc.|Liquid embolic compositions and uses thereof for treating vascular conditions|

---

WO2014159759A1|2013-03-13|2014-10-02|Biosphere Medical, Inc.|Compositions and associated methods for radioisotope-binding microparticles|

---

US20140271453A1|2013-03-14|2014-09-18|Abbott Laboratories|Methods for the early detection of lung cancer|

---

EP2999747B1|2013-05-23|2020-08-12|206 ORTHO, Inc.|Apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone|

---

USD716451S1|2013-09-24|2014-10-28|C. R. Bard, Inc.|Tissue marker for intracorporeal site identification|

---

USD715942S1|2013-09-24|2014-10-21|C. R. Bard, Inc.|Tissue marker for intracorporeal site identification|

---

USD715442S1|2013-09-24|2014-10-14|C. R. Bard, Inc.|Tissue marker for intracorporeal site identification|

---

USD716450S1|2013-09-24|2014-10-28|C. R. Bard, Inc.|Tissue marker for intracorporeal site identification|

---

US9999527B2|2015-02-11|2018-06-19|Abbott Cardiovascular Systems Inc.|Scaffolds having radiopaque markers|

---

US9700443B2|2015-06-12|2017-07-11|Abbott Cardiovascular Systems Inc.|Methods for attaching a radiopaque marker to a scaffold|

---

WO2018008761A1|2016-07-08|2018-01-11|Ｙａｎｃｈｅｒｓ株式会社|Therapeutic agent for solid cancer|

---

US10368874B2|2016-08-26|2019-08-06|Microvention, Inc.|Embolic compositions|

---

US20190358262A1|2016-12-03|2019-11-28|Juno Therapeutics, Inc.|Methods for modulation of car-t cells|

---

CN111200976A|2017-10-09|2020-05-26|微仙美国有限公司|Plug for radioactive liquid|

法律状态:
2003-04-24| STCF| Information on status: patent grant|Free format text: PATENTED CASE |

---

2005-09-13| RF| Reissue application filed|Effective date: 20050513 |

---

2006-11-09| FPAY| Fee payment|Year of fee payment: 4 |

优先权:

---

申请号 | 申请日 | 专利标题

---

US08/962,819|US6015541A|1997-11-03|1997-11-03|Radioactive embolizing compositions|

---

US09/393,886|US6214315B1|1997-11-03|1999-09-10|Radioactive embolizing compositions|

---

US09/785,274|US6562317B2|1997-11-03|2001-02-20|Radioactive embolizing compositions|US09/785,274| US6562317B2|1997-11-03|2001-02-20|Radioactive embolizing compositions|

---

US11/129,742| USRE39456E1|1997-11-03|2005-05-13|Radioactive embolizing compositions|